var title_f12_17_12560="Bohn nodule";
var content_f12_17_12560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bohn nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bohn nodules are inclusion cysts that involve the vestibular or lingual surface of the alveolar ridge in neonates and infants. They appear as single or multiple white or translucent round papules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher MA. Physical diagnosis in neonatology. Philadelphia: Lippincott-Raven Publishers; 1998:216. Copyright &copy;1998 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_17_12560=[""].join("\n");
var outline_f12_17_12560=null;
var title_f12_17_12561="Bronchiolitis radiograph";
var content_f12_17_12561=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F88283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F88283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Bronchiolitis radiographs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The above radiographs demonstrate the following findings that are consistent with bronchiolitis:",
"    <br/>",
"    1) Patchy atelectasis, in particular of the right middle lobe",
"    <br/>",
"    2) Bilateral peribronchial infiltrations with air bronchograms",
"    <br/>",
"    3) Hyper-inflation of the lungs with flattening of the diaphragms",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_17_12561=[""].join("\n");
var outline_f12_17_12561=null;
var title_f12_17_12562="Anatomy of Koch's triangle";
var content_f12_17_12562=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Schematic representation of Koch's triangle and environment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Around the compact atrioventricular (AV) node is an extended zone with transitional cells.",
"    <div class=\"footnotes\">",
"     LBB: left bundle branch; RBB: right bundle branch.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_17_12562=[""].join("\n");
var outline_f12_17_12562=null;
var title_f12_17_12563="Fibroid embolization 1 PI";
var content_f12_17_12563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F75866%7EPI%2F54882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F75866%7EPI%2F54882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibroid embolization 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagram showing superselective catheter position in the right uterine artery via left femoral arterial approach.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibroid embolization 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagram showing embolic particles being released from the catheter and into the uterine arterial branches supplying the fibroid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_17_12563=[""].join("\n");
var outline_f12_17_12563=null;
var title_f12_17_12564="Barium: Drug information";
var content_f12_17_12564=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Barium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/37/19028?source=see_link\">",
"    see \"Barium: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Digibar&trade; 190;",
"     </li>",
"     <li>",
"      E-Z Cat&reg; Dry;",
"     </li>",
"     <li>",
"      E-Z-Cat&reg;;",
"     </li>",
"     <li>",
"      E-Z-Disk&trade;;",
"     </li>",
"     <li>",
"      E-Z-Dose&trade; with Liquid Polibar Plus&reg;;",
"     </li>",
"     <li>",
"      E-Z-HD&trade;;",
"     </li>",
"     <li>",
"      E-Z-Paque&reg;;",
"     </li>",
"     <li>",
"      E-Z-Paste&reg;;",
"     </li>",
"     <li>",
"      Entero Vu&trade;;",
"     </li>",
"     <li>",
"      Entero VU&trade; 24%;",
"     </li>",
"     <li>",
"      Entero-H&trade;;",
"     </li>",
"     <li>",
"      Esopho-Cat&reg;;",
"     </li>",
"     <li>",
"      Liquid Entero Vu&trade;;",
"     </li>",
"     <li>",
"      Liquid Polibar Plus&reg;;",
"     </li>",
"     <li>",
"      Liquid Polibar&reg;;",
"     </li>",
"     <li>",
"      Maxibar&trade;;",
"     </li>",
"     <li>",
"      Polibar&reg; ACB;",
"     </li>",
"     <li>",
"      Readi-Cat&reg;;",
"     </li>",
"     <li>",
"      Readi-Cat&reg; 2;",
"     </li>",
"     <li>",
"      Sensatrast&trade;;",
"     </li>",
"     <li>",
"      Tagitol&trade; V;",
"     </li>",
"     <li>",
"      Ultra-R&reg;;",
"     </li>",
"     <li>",
"      Varibar&reg; Honey;",
"     </li>",
"     <li>",
"      Varibar&reg; Nectar;",
"     </li>",
"     <li>",
"      Varibar&reg; Pudding;",
"     </li>",
"     <li>",
"      Varibar&reg; Thin Honey;",
"     </li>",
"     <li>",
"      Varibar&reg; Thin Liquid;",
"     </li>",
"     <li>",
"      VoLumen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F139058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopaque Agents",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F139049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, oral, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-Z-Paste&reg;: 60% w/w (454 g) [vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Esopho-Cat&reg;: 3% w/w (30 g) [contains sodium benzoate; vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Paste, oral, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Varibar&reg; Pudding: 40% w/v (230 mL) [contains sodium benzoate; vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Digibar&trade; 190: 190% w/v after reconstitution (232 g) [vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-Z Cat&reg; Dry: 2% w/w after reconstitution (23 g) [orange-vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-Z-HD&trade;: 98% w/w before reconstitution (340 g) [strawberry-vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-Z-Paque&reg;: 96% w/w before reconstitution (176 g, 1200 g) [contains propylene glycol; strawberry-vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Entero Vu&trade;: 13% w/v after reconstitution (100 g) [orange-vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultra-R&reg;: 95% w/w before reconstitution (170 g) [strawberry-vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Varibar&reg; Thin Liquid: 40% w/v after reconstitution (148 g) [apple flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral/rectal, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sensatrast&trade;: 100% before reconstitution (120 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, rectal, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Polibar&reg; ACB: 96% w/w before reconstitution (397 g, 454 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-Z-Cat&reg;: 4.9% w/v (255 mL) [orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Entero VU&trade; 24%: 24% w/v (600 mL) [contains sodium benzoate; blueberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Entero-H&trade;: 80% w/v (1900 mL) [contains sodium benzoate; orange-vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Liquid Entero Vu&trade;: 13% w/v (600 mL) [contains sodium benzoate; blueberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxibar&trade;: 210% w/v (120 mL) [contains sodium benzoate; cherry-orange-vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Readi-Cat&reg; 2: 2.1% w/v (450 mL) [contains benzoic acid, sodium benzoate; apple smoothie flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Readi-Cat&reg; 2: 2.1% w/v (250 mL, 450 mL) [contains benzoic acid, sodium benzoate; banana smoothie flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Readi-Cat&reg; 2: 2.1% w/v (450 mL) [contains benzoic acid, sodium benzoate; berry smoothie flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Readi-Cat&reg; 2: 2.1% w/v (250 mL, 450 mL) [contains benzoic acid, sodium benzoate; creamy vanilla smoothie flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Readi-Cat&reg; 2: 2.1% w/v (450 mL) [contains benzoic acid, sodium benzoate; mochaccino smoothie flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tagitol&trade; V: 40% w/v (20 mL) [contains sodium benzoate; apple flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Varibar&reg; Honey: 40% w/v (250 mL) [contains sodium benzoate; apple flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Varibar&reg; Nectar: 40% w/v (240 mL) [contains sodium benzoate; apple flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Varibar&reg; Thin Honey: 40% w/v (250 mL) [contains sodium benzoate; apple flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VoLumen&reg;: 0.1% w/v (450 mL) [contains benzoic acid, sodium benzoate; blueberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral/rectal, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Liquid Polibar Plus&reg;: 105% w/v (1900 mL) [contains sodium benzoate; vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Liquid Polibar&reg;: 100% w/v (1900 mL) [contains sodium benzoate; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Readi-Cat&reg;: 1.3% w/v (450 mL, 900 mL, 1900 mL) [contains sodium benzoate; orange-vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Readi-Cat&reg; 2: 2.1% w/v (450 mL, 900 mL, 1900 mL) [contains sodium benzoate; orange-vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, rectal, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-Z-Dose&trade; with Liquid Polibar Plus&reg;: 105% w/v (650 mL) [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-Z-Disk&trade;: 648 mg [half-inch diameter]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F139047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F139050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diagnostic aid for computed tomography or x-ray examinations of the GI tract",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F139052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to barium or any component of the formulation; known or suspected obstruction of the colon, known or suspected GI tract perforation, suspected tracheoesophageal fistula, obstructing lesions of small intestine, pyloric stenosis",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Specific agents may also be contraindicated with inflammation or neoplastic lesions of the rectum, recent rectal biopsy; use in infants with swallowing disorders; newborns with complete duodenal or jejunal obstruction with suspected distal small bowel or colon obstruction; very small preterm infants and young babies requiring small volumes of contrast media; infants and young children with possible leakage from GI tract (eg, necrotizing enterocolitis, unexplained pneumoperitoneum, gasless abdomen, bowel or esophageal perforation, postoperative anastomosea)",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F139054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy for use during pregnancy have not been established. In general, elective radiography of the abdomen is avoided during pregnancy unless essential for diagnosis.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F139055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Barium sulfate is not systemically absorbed.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (E-Z-Paste Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60% (454 g): $58.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Esopho-Cat Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% (30 g): $6.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Enema",
"     </b>",
"     (E-Z-Dose Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     105% (650 mL): $34.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Polibar ACB Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     96% (394 g): $11.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (E-Z-Cat Dry Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (50): $216.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Entero VU Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     13% (12): $290.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paste",
"     </b>",
"     (Varibar Pudding Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (230 mL): $60.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Entero VU Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     13% (600 mL): $35.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     24% (600 mL): $39.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Liquid Polibar Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100% (1900 mL): $36.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Liquid Polibar Plus Combination)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     105% (1900 mL): $47.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Maxibar Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     210% (120 mL): $5.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Readi-Cat 2 Combination)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.1% (450 mL): $5.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Readi-Cat 2 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (450 mL): $4.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.1% (450 mL): $6.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Readi-Cat Combination)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.3% (450 mL): $6.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Tagitol V Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (60 mL): $30.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Varibar Honey Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (250 mL): $65.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Varibar Nectar Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (240 mL): $16.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Varibar Thin Honey Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (250 mL): $65.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (VoLumen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (450 mL): $8.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Digibar 190 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     190% (120 mL): $7.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (E-Z-HD Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     98% (135 mL): $7.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (E-Z-Paque Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     96% (176 g): $3.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Varibar Thin Liquid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40% (148 g): $6.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bar-Test Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     650 mg (100): $170.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (E-Z-Disk Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     700 mg (100): $215.09",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F139056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Barium Sulfuricum (PL);",
"     </li>",
"     <li>",
"      Falibaryt (PL);",
"     </li>",
"     <li>",
"      Micropaque (PL);",
"     </li>",
"     <li>",
"      Microtrast (PL);",
"     </li>",
"     <li>",
"      Prontobario (PL)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Obstetric Practice, &ldquo;ACOG Committee Opinion. Guidelines for Diagnostic Imaging During Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2004, 104(3):647-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/17/12564/abstract-text/15339791/pubmed\" id=\"15339791\" target=\"_blank\">",
"        15339791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9180 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-FC043B0C43-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_17_12564=[""].join("\n");
var outline_f12_17_12564=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139057\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139058\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139049\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139047\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139050\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139052\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139054\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139055\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323007\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139056\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9180\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9180|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/37/19028?source=related_link\">",
"      Barium: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_17_12565="Menotropins: Drug information";
var content_f12_17_12565=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Menotropins: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/13/25812?source=see_link\">",
"    see \"Menotropins: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Menopur&reg;;",
"     </li>",
"     <li>",
"      Repronex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Menopur&reg;;",
"     </li>",
"     <li>",
"      Repronex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F192658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gonadotropin;",
"     </li>",
"     <li>",
"      Ovulation Stimulator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F192625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Repronex&reg;:",
"     </b>",
"     I.M., SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Induction of ovulation in patients with oligoanovulation (Females):",
"     </i>",
"     Initial: 150 units daily for the first 5 days of treatment. Adjustments should not be made more frequently than once every 2 days and should not exceed 75-150 units per adjustment. Maximum daily dose should not exceed 450 units and dosing beyond 12 days is not recommended. If patient's response is appropriate, hCG 5000-10,000 units should be given one day following the last dose of Repronex&reg;. Hold dose if serum estradiol is &gt;2000 pg/mL, if the ovaries are abnormally enlarged, or if abdominal pain occurs; the patient should also be advised to refrain from intercourse. May repeat process if follicular development is inadequate or if pregnancy does not occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Assisted reproductive technologies (Females):",
"     </i>",
"     Initial (in patients who have received GnRH agonist or antagonist pituitary suppression): 225 units; adjustments in dose should not be made more frequently than once every 2 days and should not exceed more than 75-150 units per adjustment. The maximum daily doses of Repronex&reg; given should not exceed 450 units and dosing beyond 12 days is not recommended. Once adequate follicular development is evident, hCG (5000-10,000 units) should be administered to induce final follicular maturation in preparation for oocyte retrieval. Withhold treatment when ovaries are abnormally enlarged on last day of therapy (to reduce chance of developing OHSS).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Menopur&reg;:",
"     </b>",
"     SubQ:",
"     <i>",
"      Assisted reproductive technologies (ART):",
"     </i>",
"     Initial (in patients who have received GnRH agonist for pituitary suppression): 225 units; adjustments in dose should not be made more frequently than once every 2 days and should not exceed more than 150 units per adjustment. The maximum daily dose given should not exceed 450 units and dosing beyond 20 days is not recommended. Once adequate follicular development is evident, hCG should be administered to induce final follicular maturation in preparation for oocyte retrieval. Withhold treatment when ovaries are abnormally enlarged on last day of therapy (to reduce chance of developing OHSS).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Spermatogenesis (Males) (unlabeled use):",
"     </i>",
"     I.M.: Following pretreatment with hCG: 75 units 3 times/week and hCG 2000 units twice weekly until sperm is detected in the ejaculate (4-6 months); may then be increased to menotropins 150 units 3 times/week",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16317926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16317927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F192607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Menopur&reg;:  75 units [supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Repronex&reg;: 75 units [supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F192593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F192609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Menopur&reg;: SubQ: Administer to alternating sites of the abdomen; when administration to the lower abdomen is not possible, the injection may be given into the thigh.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Repronex&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Administer deep in a large muscle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: Administer to alternating sites of the lower abdomen.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F192608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Female:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     In conjunction with hCG to induce ovulation and pregnancy in infertile females experiencing oligoanovulation or anovulation when the cause of anovulation is functional and not caused by primary ovarian failure (Repronex&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Stimulation of multiple follicle development in ovulatory patients as part of an assisted reproductive technology (ART) (Menopur&reg;, Repronex&reg;)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F2998790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Male: Stimulation of spermatogenesis in primary or secondary hypogonadotropic hypogonadism",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F192665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Repronex&reg; may be confused with Regranex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F192656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects may vary according to specific product, route, and/or dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (up to 34%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (up to 18%), nausea (up to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: OHSS (up to 13%, dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (4% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, malaise, migraine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast tenderness, hot flashes, menstrual irregularities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramping, abdominal fullness, constipation, diarrhea, enlarged abdomen, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Ectopic pregnancy, ovarian disease, vaginal hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site edema/pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough increased, respiratory disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection, flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Frequency not defined:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Stroke, tachycardia, thrombosis (venous or arterial)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Angioedema, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Adnexal torsion, hemoperitoneum, ovarian enlargement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Limb necrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Acute respiratory distress syndrome, atelectasis, dyspnea, embolism, laryngeal edema, pulmonary infarction, tachypnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F192612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to menotropins or any component of the formulation; primary ovarian failure as indicated by a high follicle-stimulating hormone (FSH) level; uncontrolled thyroid and adrenal dysfunction; abnormal bleeding of undetermined origin; intracranial lesion (ie, pituitary tumor); ovarian cyst or enlargement not due to polycystic ovary syndrome; infertility due to any cause other than anovulation (except candidates for",
"     <i>",
"      in vitro",
"     </i>",
"     fertilization); sex hormone-dependent tumors of the reproductive tract and accessory organs; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F192597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian enlargement: May be accompanied by abdominal distention or abdominal pain and generally regresses without treatment within 2-3 weeks. If ovaries are abnormally enlarged on the last day of treatment, withhold hCG to reduce the risk of ovarian hyperstimulation syndrome (OHSS).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian hyperstimulation syndrome (OHSS): OHSS is characterized by severe ovarian enlargement, abdominal pain/distention, nausea, vomiting, diarrhea, dyspnea, and oliguria, and may be accompanied by ascites, pleural effusion, hypovolemia, electrolyte imbalance, hemoperitoneum, and thromboembolic events. If severe hyperstimulation occurs, stop treatment and hospitalize patient. This syndrome develops rapidly with 24 hours to several days and generally occurs during the 7-10 days immediately following treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary effects: Serious pulmonary conditions (atelectasis, acute respiratory distress syndrome, and exacerbation of asthma) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: In association with and separate from ovarian hyperstimulation syndrome (OHSS), thromboembolic events have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Safety and efficacy have not been established in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician: These medications should only be used by physicians who are thoroughly familiar with infertility problems and their management.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiple births: May result from the use of these medications; advise patients of the potential risk of multiple births before starting the treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F192603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F192614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ectopic pregnancy and congenital abnormalities have been reported. The incidence of congenital abnormality is similar during natural conception.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F192627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F192613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Menopur Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 unit (1): $124.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Repronex Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 unit (1): $154.02",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F192605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     hCG levels, serum estradiol; vaginal ultrasound; in cases of suspected OHSS, monitor fluid intake and output, weight, hematocrit, serum and urinary electrolytes, urine specific gravity, BUN and creatinine, and abdominal girth",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F192615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      H.M.G. Organon (ES);",
"     </li>",
"     <li>",
"      HMG (KP);",
"     </li>",
"     <li>",
"      HMG Lepori (ES);",
"     </li>",
"     <li>",
"      HMG Massone[inj.] (AR);",
"     </li>",
"     <li>",
"      Humegon (AR, AU, BF, BJ, CI, DE, ET, GH, GM, GN, GR, HN, IN, IT, KE, KP, LR, LU, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Menogon (FR, HK, PH, PK, SG, TH);",
"     </li>",
"     <li>",
"      Menogon 75 (AE, BH, CY, EG, HK, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Menopur (AE, AT, BE, BH, CH, CL, CY, CZ, DK, EG, FI, GB, HK, IE, IL, IQ, IR, JO, KP, KW, LB, LY, NO, OM, PH, PL, PT, QA, SA, SE, SY, TH, TW, YE);",
"     </li>",
"     <li>",
"      Merional (GB);",
"     </li>",
"     <li>",
"      Pergogreen (NZ);",
"     </li>",
"     <li>",
"      Pergonal (AR, CZ, DE, ES, GR, HN, HR, HU, NL, RU, UY);",
"     </li>",
"     <li>",
"      Pergonal 500 (AE, BG, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Pergonal 75 75 (AT);",
"     </li>",
"     <li>",
"      Progonadyl (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F192596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Actions occur as a result of both follicle stimulating hormone (FSH) effects and luteinizing hormone (LH) effects; menotropins stimulate the development and maturation of the ovarian follicle (FSH), cause ovulation (LH), and stimulate the development of the corpus luteum (LH); in males it stimulates spermatogenesis (LH)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F192611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion: Urine (~10% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Association of Clinical Endocrinologists, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients &minus; 2002 Update,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2002, 8(6):440-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/17/12565/abstract-text/15260010/pubmed\" id=\"15260010\" target=\"_blank\">",
"        15260010",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9607 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_17_12565=[""].join("\n");
var outline_f12_17_12565=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192622\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192623\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192658\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192625\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317926\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317927\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192607\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192593\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192609\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192608\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2998790\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192665\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192656\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192612\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192597\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299664\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221521\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192603\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192614\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192627\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192613\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192605\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192615\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192596\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192611\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9607\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9607|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/13/25812?source=related_link\">",
"      Menotropins: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_17_12566="Carmustine: Pediatric drug information";
var content_f12_17_12566=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carmustine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"    see \"Carmustine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/48/22277?source=see_link\">",
"    see \"Carmustine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F146512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      BiCNU&reg;;",
"     </li>",
"     <li>",
"      Gliadel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F146513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      BiCNU&reg;;",
"     </li>",
"     <li>",
"      Gliadel Wafer&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Alkylating Agent (Nitrosourea)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"      see \"Carmustine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. infusion (refer to individual protocols):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 200-250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 4-6 weeks as a single dose; next dose is to be determined based on clinical and hematologic response to the previous dose (a repeat course should not be given until platelets are &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and leukocytes are &gt;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     BMT-conditioning agent: 300-600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over at least 2 hours or may be divided into 2 doses administered 12 hours apart or 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 12 hours for 6 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 150-200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 6 weeks as a single dose or divided into 75-100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose on 2 successive days; next dose is to be determined based on clinical and hematologic response to the previous dose (a repeat course should not be given until platelets are &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and leukocytes are &gt;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intracranial implant (wafer): Adults: Place 8 wafers (total dose: 61.6 mg) in the resection cavity; should the size and shape not accommodate 8 wafers, the maximum number of wafers as allowed should be placed",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F146489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BiCNU&reg;: 100 mg [supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Wafer, for implantation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gliadel&reg;: 7.7 mg (8s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F146473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Reconstitute 100 mg vial with 3 mL sterile dehydrated (absolute) alcohol followed by addition of 27 mL SWI. Further dilute the 3.3 mg of carmustine per mL solution with D",
"     <sub>",
"      5",
"     </sub>",
"     W in a glass or polyolefin container to a final concentration of 0.2-1 mg/mL and administer by I.V. infusion over 1-2 hours to prevent vein irritation; rapid I.V. carmustine infusion may result in flushing, suffusion of the conjunctiva, hypotension, and agitation; carmustine has also been administered over 15-45 minutes diluted in 100-250 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W with monitoring for vein irritation; burning sensation and pain at I.V. site can be decreased with reduction of infusion rate and further dilution of solution or placing ice pack on I.V. site; flush line before and after carmustine administration to ensure vein patency. Maximum rate of infusion for high-dose carmustine: &le;3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /minute.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F146558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, aztreonam, cefepime, etoposide phosphate, filgrastim, fludarabine, gemcitabine, granisetron, melphalan, ondansetron, piperacillin/tazobactam, sargramostim, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Cisplatin, fluorouracil.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store vial at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from light and heat; discard vial if oily film is found on the bottom of the vial; reconstituted solution is stable for 8 hours at room temperature, 24 hours when refrigerated, or 48 hours when refrigerated after further dilution in D",
"     <sub>",
"      5",
"     </sub>",
"     W in a glass bottle to a concentration of 0.1 mg/mL (defined in the study as &lt;10% loss of potency) (Favier, 2001); incompatible with sodium bicarbonate; adsorption of carmustine to plastics and polyvinyl chloride-based infusion containers has been documented. Store Gliadel&reg; wafers at or below -20&deg;C (-4&deg;F). Unopened foil pouches may be kept at room temperature for a maximum of 6 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Treatment of brain tumors (glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumor); multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas (relapsed or refractory) (FDA approved in adults); has also been used in the treatment of malignant melanoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Wafer (implant): Adjunct to surgery in patients with recurrent glioblastoma multiforme; adjunct to surgery and radiation in patients with newly diagnosed high grade malignant glioma (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2136823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Carmustine may be confused with bendamustine, lomustine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F146557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      I.V.:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia (with high doses), chest pain, flushing (with rapid infusion), hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Ataxia, dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Ethanol intoxication (with high doses), headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hyperpigmentation/skin burning (after skin contact)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (common; dose related), vomiting (common; dose related), mucositis (with high doses), toxic enterocolitis (with high doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (common; onset: 5-6 weeks; recovery: after 1-2 weeks), thrombocytopenia (common: onset: ~4 weeks; recovery: after 1-2 weeks), anemia, neutropenic fever, secondary malignancies (acute leukemia, bone marrow dysplasias)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, bilirubin increased, hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease; with high doses), transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions (burning, erythema, necrosis, pain, swelling)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctival suffusion (with rapid infusion), neuroretinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Kidney size decreased, progressive azotemia, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Interstitial pneumonitis (with high doses), pulmonary fibrosis, pulmonary hypoplasia, pulmonary infiltrates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, infection (with high doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Wafer:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain, deep thrombophlebitis, facial edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, ataxia, brain edema, confusion, depression, facial paralysis, fever, hallucination, headache, hypesthesia, intracranial hypertension, meningitis, pain, seizure (grand mal), somnolence, speech disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Abnormal wound healing, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine: Diabetes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Abscess",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal thinking, allergic reaction, amnesia, aspiration pneumonia, cerebral hemorrhage, cerebral infarction, coma, cyst formation, diplopia, dizziness, dysphagia, eye pain, fecal incontinence, gastrointestinal hemorrhage, hydrocephalus, hyperglycemia, hyper-/hypotension, hypokalemia, hyponatremia, insomnia, leukocytosis, monoplegia, neck pain, paranoia, peripheral edema, sepsis, thrombocytopenia, urinary incontinence, visual field defect",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to carmustine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with caution to patients with depressed platelet, leukocyte or erythrocyte counts and in patients with renal or hepatic impairment; dosage reduction is recommended in patients with compromised bone marrow function (decreased leukocyte and platelet counts). Should be administered under the supervision of an experienced cancer chemotherapy physician",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Bone marrow suppression, notably thrombocytopenia and leukopenia, may lead to bleeding and overwhelming infection in an already compromised patient",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; myelosuppressive effects will last for at least 6 weeks after a dose, do not give courses more frequently than every 6 weeks because the toxicity is cumulative; delayed-onset pulmonary fibrosis (sometimes fatal) has occurred up to 17 years after carmustine treatment in children and adolescents who received cumulative doses ranging from 770-1800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     combined with cranial radiotherapy for intracranial tumors. Acute leukemia has been reported in patients receiving long-term carmustine. May cause fetal harm when administered to a pregnant woman; carmustine is potentially carcinogenic.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Cases of intracerebral mass effect unresponsive to corticosteroids, including one case leading to brain herniation, have been reported. Monitor patients receiving Gliadel&reg; implant for seizures, intracranial infections, abnormal wound healing, and brain edema. Carmustine injection diluent contains absolute alcohol which can cause an &ldquo;alcohol flushing syndrome&rdquo; in susceptible patients; use with caution in patients with aldehyde dehydrogenase-2 deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F146483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May enhance the myelosuppressive effect of Carmustine. Management: Consider alternatives to cimetidine in patients receiving carmustine.  If the combination cannot be avoided, monitor for enhanced carmustine myelotoxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melphalan: May enhance the adverse/toxic effect of Carmustine. Specifically, melphalan may sensitize patients to carmustine lung toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F146485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F146498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenicity and embryotoxicity have been demonstrated in animal studies. Carmustine can cause fetal harm if administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should avoid becoming pregnant while on treatment.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count; baseline pulmonary function tests and tests during treatment (forced vital capacity; carbon monoxide diffusing capacity); liver function and renal function tests; monitor blood pressure and infusion site during administration",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits key enzymatic reactions involved with DNA synthesis; carbamoylation of amino acids in proteins; interferes with the normal function of DNA and RNA by alkylation and forms DNA-protein cross-links",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Readily crosses the blood-brain barrier since it is highly lipid soluble; CSF:plasma ratio &gt;90%; distributes into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Denitrosation through action of microsomal enzymes; some enterohepatic circulation occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal: 20-70 minutes (active metabolites may persist for days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &sim;60% to 70% excreted as metabolites in the urine and 6% to 10% excreted as CO",
"     <sub>",
"      2",
"     </sub>",
"     by the lungs",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1045767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/48/22277?source=see_link\">",
"      see \"Carmustine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report occurrence of fever, sore throat, unusual bleeding or bruising to physician; may discolor skin brown; women of childbearing potential should avoid becoming pregnant while on carmustine therapy",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1045778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Myelosuppressive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     WBC: Moderate (nadir: 5-6 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Platelets: Severe (nadir: 4-5 weeks)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronin PA, Mahaley MS Jr, Rudnick SA, et al, &ldquo;Prediction of BCNU Pulmonary Toxicity in Patients With Malignant Gliomas,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1980, 303(4):183-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/17/12566/abstract-text/7383088/pubmed\" id=\"7383088\" target=\"_blank\">",
"        7383088",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Colvin M, Hartner J, and Summerfield M, &ldquo;Stability of Carmustine in the Presence of Sodium Bicarbonate,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1980, 37(5):677-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/17/12566/abstract-text/7386477/pubmed\" id=\"7386477\" target=\"_blank\">",
"        7386477",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunkel IJ, Garvin JH Jr, Goldman S, et al, &ldquo;High Dose Chemotherapy With Autologous Bone Marrow Rescue for Children With Diffuse Pontine Brain Stem Tumors. Children's Cancer Group,&rdquo;",
"      <i>",
"       J Neurooncol",
"      </i>",
"      , 1998, 37(1):67-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/17/12566/abstract-text/9525840/pubmed\" id=\"9525840\" target=\"_blank\">",
"        9525840",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Favier M, De Cazanove F, Coste A, et al, \"Stability of Carmustine in Polyvinyl Chloride Bags and Polyethylene-Lined Trilayer Plastic Containers,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2001, 58(3):238-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/17/12566/abstract-text/11217179/pubmed\" id=\"11217179\" target=\"_blank\">",
"        11217179",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Driscoll BR, Hasleton PS, Taylor PM, et al, &ldquo;Active Lung Fibrosis Up to 17 Years After Chemotherapy With Carmustine (BCNU) in Childhood,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1990, 323(6):378-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/17/12566/abstract-text/2370889 /pubmed\" id=\"2370889 \" target=\"_blank\">",
"        2370889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Papadakis V, Dunkel IJ, Cramer LD, et al, \"High-Dose Carmustine, Thiotepa and Etoposide Followed by Autologous Bone Marrow Rescue for the Treatment of High Risk Central Nervous System Tumors,\"",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2000, 26(2):153-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/17/12566/abstract-text/10918425/pubmed\" id=\"10918425\" target=\"_blank\">",
"        10918425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13118 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-CC23815824-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_17_12566=[""].join("\n");
var outline_f12_17_12566=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708652\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146512\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146513\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045770\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045762\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146489\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146473\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045774\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146558\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045765\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045773\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136823\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146557\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045777\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045761\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045760\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298978\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146483\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146485\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146498\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045769\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045759\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045776\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045767\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045778\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13118\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13118|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=related_link\">",
"      Carmustine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/48/22277?source=related_link\">",
"      Carmustine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_17_12567="Palpation of palmar fascia";
var content_f12_17_12567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69444%7ERHEUM%2F70486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69444%7ERHEUM%2F70486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palpation of the palmar fascia for nodularity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The hand is placed in the palm up position. Each of the four digits are passively stretched in extension, noting any differences in flexibility and tendon scarring between the fingers. Next, the tendons are palpated for thickening or nodularity along their course through the palm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dupuytren's contracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 306px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nodular fibrosing lesions with bands radiating distally are features of Dupuytren's contracture. The ulnar side of the hand is affected, with the 4th and 5th fingers usually involved first.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996. Copyright &copy; 1996 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_17_12567=[""].join("\n");
var outline_f12_17_12567=null;
var title_f12_17_12568="Diseases potentially acquired by travel to Southeast Asia";
var content_f12_17_12568=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diseases potentially acquired by travel to Southeast Asia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/17/12568/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/17/12568/contributors\">",
"     David Murdoch, MD, MSc, DTM&amp;H, FRACP, FRCPA, FFSc(RCPA)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/17/12568/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/17/12568/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/17/12568/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/17/12568/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/17/12568/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Southeast Asia encompasses the region from southern China through the Indochina peninsula and islands bordering the South China Sea to the island of New Guinea (see figure on",
"    <a class=\"external\" href=\"file://www.cdc.gov/travel/seasia.htm\">",
"     www.cdc.gov/travel/seasia.htm",
"    </a>",
"    ). The countries within this region are Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar (Burma), the Philippines, Singapore, Thailand, and Viet Nam. The region straddles the equator between latitudes of 30&ordm;N to 10&ordm;S and comprises rain forests, savanna, tropical beaches, and volcanic islands.",
"   </p>",
"   <p>",
"    The whole of Southeast Asia is seeing increasing numbers of travelers. Some areas, such as Bali, Singapore, Bangkok, and the resort islands of Thailand and Malaysia are well-established tourist destinations; other areas, including Viet Nam and Cambodia, have been recently reopened to foreign visitors. The health risks vary considerably from region to region within Southeast Asia, although there are only a few places (eg, Singapore) where the risks do not differ appreciably from western Europe, North America, and Australia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SURVEILLANCE DATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest contemporary experience in travel-related disease in developing countries comes from GeoSentinel, which is the global surveillance network of the International Society of Travel Medicine and the Centers for Disease Control and Prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2006 report from 30 GeoSentinel sites in developed countries provided clinical-based surveillance information on 17,353 ill travelers who had returned from developing countries and were seen between June 1996 and August 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/1\">",
"     1",
"    </a>",
"    ]. It was estimated that up to 8 percent of travelers to developing countries are ill enough to seek health care while abroad or after returning home.",
"   </p>",
"   <p>",
"    The following observations were noted in the 2793 ill travelers who had returned from Southeast Asia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients (72 percent) presented within one month after returning from travel, and 11 percent required hospitalization.",
"     </li>",
"     <li>",
"      The primary manifestations in over 60 percent of returned travelers fell into four major syndrome categories: systemic febrile illness without localizing findings, acute diarrhea, dermatologic disorders, and nondiarrheal gastrointestinal disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among patients with a systemic febrile illness, 32 percent had dengue, 13 percent had malaria, 3 percent had mononucleosis (due to Epstein-Barr virus or cytomegalovirus), 3 percent had Salmonella typhi or S. paratyphi infection, 2 percent had a rickettsial infection, and no cause was reported in 45 percent.",
"     </li>",
"     <li>",
"      Among patients with acute diarrhea, 36 percent had bacterial infection (mostly Campylobacter and nontyphoidal salmonella), 24 percent had parasitic infection (mostly giardiasis and amebiasis), a small number had viral infection, and 36 percent had unspecified acute diarrhea.",
"     </li>",
"     <li>",
"      Among patients with dermatologic disorders, the most common were an insect bite, with or without superinfection, cutaneous larva migrans, an animal bite requiring rabies prophylaxis, skin abscess, and an allergic rash or reaction.",
"     </li>",
"     <li>",
"      Among patients with a nondiarrheal gastrointestinal disorder, 59 percent had intestinal nematode infection (mostly Strongyloides) and 18 percent had gastritis or peptic ulcer disease. The remaining patients had acute hepatitis, hemorrhoids, or constipation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A later report from GeoSentinel specifically evaluated fever, which was the chief reason for seeking care in 28 percent of almost 25,000 ill returned travelers who were seen between 1997 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39304?source=see_link\">",
"     \"Evaluation of fever in the returning traveler\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among ill travelers who had returned from Southeast Asia, fever was present in 33 percent with the following distribution of causes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      34 percent had a systemic febrile illness, mostly due to dengue (18 percent) and malaria (7 percent)",
"     </li>",
"     <li>",
"      17 percent had a diarrheal illness",
"     </li>",
"     <li>",
"      17 percent had a respiratory illness",
"     </li>",
"     <li>",
"      22 percent had an undiagnosed febrile illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ARTHROPOD-BORNE DISEASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaria endemic areas exist in all countries in this region except Singapore and Brunei. Within endemic areas, transmission occurs year round. Country-specific risk areas are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cambodia &mdash; Nationwide, except no risk in Phnom Penh and close around Tonle Sap. Malaria does occur in the tourist area of Angkor Wat.",
"     </li>",
"     <li>",
"      Indonesia &mdash; High risk in most areas of East Nusu Tenggara, Maluku, North Maluku, Papua, and West Papua. In other parts of the country there is some risk, except in Jakarta, in cities and urban areas, and main tourist resorts.",
"     </li>",
"     <li>",
"      Laos &mdash; Nationwide, except no risk in Vientiane.",
"     </li>",
"     <li>",
"      Malaysia &mdash; The highest risk is in Sabah and Sarawak, but also in remote areas of Malaya (especially the Cameron Highlands). Urban and coastal areas (including resorts) are risk free.",
"     </li>",
"     <li>",
"      Myanmar &mdash; Nationwide at altitudes below 1000 m, excluding the main urban areas of Yangon and Mandalay. Risk is highest in remote rural, hilly, and forested areas.",
"     </li>",
"     <li>",
"      Philippines &mdash; The risk exists throughout the year in areas below 600 m elevation, except in the provinces of Aklan, Bilaran, Bohol, Camiquin, Capiz, Catanduanes, Cebu, Guimaras, Iloilo, Leyte, Masbate, northern Samar, Sequijor and metropolitan Manila. No risk is considered to exist in urban areas or in the plains.",
"     </li>",
"     <li>",
"      Thailand &mdash; The risk is largely confined to the borders with Cambodia and Myanmar. There is no risk in the major cities and tourist resorts (Bangkok, Chiang Mai, Pattaya, Phuket, and Samui).",
"     </li>",
"     <li>",
"      Vietnam &mdash; Nationwide risk, excluding urban centers, the Red River delta, and the coastal plain areas of central Viet Nam. High risk areas are the highland areas below 1500 m (particularly south of latitude 18&ordm;N), including the three central highland provinces of Dak Lak, Gia Lai, and Kon Tum, and the southern provinces of Ca Mau, Bac Lieu, and Tay Nimh.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Drug-resistant malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-resistant malaria has been a major problem in Southeast Asia, with chloroquine-resistant Plasmodium falciparum predominating in virtually all endemic areas.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     Mefloquine",
"    </a>",
"    resistance occurs in the Thai-Myanmar and Thai-Cambodian border regions. The following are recommended prophylactic agents for most travelers to malarious areas (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=see_link\">",
"     \"Prevention of malaria infection in travelers\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       Mefloquine",
"      </a>",
"      &mdash; Cambodia (except along the border with Thailand), Indonesia, Laos, Malaysia, Myanmar, Viet Nam, and the Philippines",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       Doxycycline",
"      </a>",
"      &mdash; Cambodia (along the border with Thailand), Thailand (in areas bordering Cambodia and Myanmar)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Japanese encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Japanese encephalitis is an arboviral encephalitis that is endemic throughout much of tropical east Asia. Issues related to Japanese encephalitis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5208?source=see_link\">",
"     \"Japanese encephalitis: Epidemiology, diagnosis, treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dengue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dengue",
"    <span class=\"nowrap\">",
"     fever/dengue",
"    </span>",
"    hemorrhagic fever is an arboviral disease endemic throughout Southeast Asia. The main vector in this region is the daytime biting mosquito Aedes aegypti, which typically breeds near human habitation. Most cases are reported from urban areas with high population densities. Unusually high levels of dengue fever activity have been experienced by many countries in Southeast Asia including Malaysia, Cambodia, Viet Nam, Thailand, Philippines, Indonesia, and Myanmar. In 2005, Singapore experienced its worst recorded outbreak of dengue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4984?source=see_link\">",
"     \"Epidemiology of dengue virus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Typhus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both scrub typhus (caused by Orientia tsutsugamushi) and murine typhus (caused by Rickettsia typhi) are endemic in some regions of Southeast Asia. Scrub typhus occurs in certain rural areas with scrub vegetation, but has also been acquired in suburban Bangkok [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26852?source=see_link\">",
"     \"Scrub typhus: Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Murine typhus is transmitted to humans by rat or cat fleas and occurs most commonly in urban settings; there have been several reports of travelers acquiring murine typhus in Southeast Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27796?source=see_link\">",
"     \"The epidemiology and clinical manifestations of murine typhus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Yellow fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no risk for yellow fever in Southeast Asia. However, due to the presence of the mosquito vector of yellow fever (Aedes aegypti), all countries in the region require travelers to have a yellow fever vaccination certificate if they are coming from specified areas in South America or sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15705?source=see_link\">",
"     \"Yellow fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chikungunya fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chikungunya is an arbovirus transmitted by mosquitoes that is endemic to West Africa and causes acute febrile polyarthralgia and arthritis. The name chikungunya is derived from a local language of Tanzania meaning \"that which bends up\" or \"stooped walk\" because of the incapacitating arthralgia caused by the disease. Chikungunya fever is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15576?source=see_link\">",
"     \"Chikungunya fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FOODBORNE AND WATERBORNE DISEASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Travelers' diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Southeast Asia (with the exception of Singapore) is regarded as a high risk area for the development of travelers' diarrhea (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29145?source=see_link\">",
"     \"Travelers' diarrhea\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/6\">",
"     6",
"    </a>",
"    ]. The most commonly isolated pathogens are similar to other high risk areas of the world with the possible exception of Vibrio parahaemolyticus, which is more common in the region and is associated with seafood ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/7\">",
"     7",
"    </a>",
"    ]. In Thailand, enteric pathogens have developed resistance to most classes of antibiotics used to treat diarrhea, including the newer fluoroquinolones and macrolides [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cholera",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1999, over 2500 cases of cholera were reported from countries of Southeast Asia, including Cambodia, Malaysia, Philippines, Singapore, and Viet Nam, although the number of cases has fallen since this time. In 2003, there was only one reported case from the region in Singapore. The risk for travelers is thus low and, under normal circumstances, cholera vaccination is not recommended for travelers to the region. However, there remains a risk in the neighboring countries of",
"    <span class=\"nowrap\">",
"     China/Hong",
"    </span>",
"    Kong (229 cases in 2003) and India (2893 cases in 2003). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link\">",
"     \"Overview of Vibrio cholerae infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29768?source=see_link\">",
"     \"Pathogenesis of Vibrio cholerae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Typhoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typhoid is endemic throughout most of Southeast Asia. The risk is very low for travelers to Singapore. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=see_link\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hepatitis A and hepatitis E",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis A virus is endemic throughout Southeast Asia, although there is a very low risk for travelers to Singapore. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=see_link\">",
"     \"Overview of hepatitis A virus infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Foci of epidemic hepatitis E virus transmission has been recognized throughout Southeast Asia, including Viet Nam, Indonesia and Thailand [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. In addition, a seroprevalence of 10 to 15 percent has been found among Singaporeans [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33976?source=see_link\">",
"     \"Hepatitis E virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Poliomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Western Pacific region (which includes all Southeast Asian countries except Indonesia and Myanmar) was declared free of poliomyelitis in 2001; however, an outbreak occurred in Indonesia in 2005. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36553?source=see_link\">",
"     \"Polio and infectious diseases of the anterior horn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Schistosomiasis and other fluke infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schistosomiasis due to Schistosoma japonicum is endemic in southern Philippines and Sulawesi (Indonesia), and there are small foci of Schistosoma mekongi in the Mekong River delta. Fasciolopsiasis (giant intestinal fluke) and paragonimiasis (lung fluke) can be acquired in most countries of the region. Clonorchiasis (oriental liver fluke) is particularly common in Indochina, while opisthorchiasis (cat liver fluke) is found in Indochina, the Philippines, and Thailand. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7398?source=see_link\">",
"     \"Diagnosis of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OTHER INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Avian influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since 2003, human infections with avian influenza A (H5N1) virus have occurred in Southeast Asia, with many fatalities [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/13\">",
"     13",
"    </a>",
"    ]. The largest number of cases has occurred in Viet Nam, although cases have also occurred in Thailand, Cambodia, and Indonesia. Avian influenza is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14090?source=see_link\">",
"     \"Epidemiology, transmission, and pathogenesis of avian influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Severe acute respiratory syndrome (SARS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;SARS is a respiratory illness caused by a novel coronavirus, SARS-associated coronavirus (SARS-CoV) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/14\">",
"     14",
"    </a>",
"    ]. The disease is believed to have originated in southern China at the end of 2002. In February 2003 it crossed into Hong Kong and, a few days later, to Viet Nam, Singapore, Canada, and Germany, and eventually spread to more than two dozen countries in North and South America, Europe, and Asia. In the East Asia region, Taiwan also experienced a large outbreak (",
"    <a class=\"external\" href=\"file://www.wpro.who.int/sars\">",
"     www.wpro.who.int/sars",
"    </a>",
"    ). In July 2003, new cases were no longer being reported, and SARS outbreaks worldwide were considered contained. Two isolated cases of SARS in laboratory workers occurred in Singapore in September 2003 and in Taiwan in December 2003. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17753?source=see_link\">",
"     \"Severe acute respiratory syndrome (SARS)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of people in Southeast Asia infected with HIV has increased dramatically. The highest rates are seen in Cambodia (three percent of adults infected), Thailand (two percent of adults), and Myanmar (two percent of adults) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/15\">",
"     15",
"    </a>",
"    ]. Prostitution has played a relatively important role in the spread of HIV in the region. In 1997, 13 percent of Thai sex workers in urban areas were infected with HIV; the rate was approximately 25 percent outside urban areas. Recent surveillance indicates a slow decrease in incidence of HIV infection in this occupational group. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=see_link\">",
"     \"The global human immunodeficiency virus pandemic\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other sexually transmitted diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexually transmitted diseases other than HIV infection are a major public health problem in parts of Southeast Asia. Contact with sex workers involves a high risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Hepatitis B and hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B virus is highly endemic throughout Southeast Asia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of hepatitis C among residents of the region ranges from 0.54 percent in Singapore to 6.1 percent in Viet Nam [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18554?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Melioidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melioidosis is caused by Burkholderia pseudomallei, a gram-negative bacillus that can be isolated from soil and water. It is endemic throughout Southeast Asia, especially in rural communities, with seasonal peaks occurring during the rainy seasons. Melioidosis has been reported in travelers to endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39577?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of melioidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Penicillium marneffei infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillium marneffei is a fungus that is endemic in Southeast Asia. It causes disseminated infection in immunocompromised individuals, especially those with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/18\">",
"     18",
"    </a>",
"    ]. In some parts of the region, it is the third most common opportunistic infection in HIV-infected people. Although the exact route of transmission has not been determined, the fungus is closely associated with bamboo rats. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33302?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Penicillium marneffei infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Plague",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of plague are still being reported from Myanmar and Viet Nam, although travelers are very rarely affected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24774?source=see_link\">",
"     \"Epidemiology, microbiology and pathogenesis of plague (Yersinia pestis infection)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11512?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Rabies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rabies is endemic throughout Southeast Asia. Through the efforts of rabies control programs, the prevalence of human and canine rabies has decreased significantly in some countries. However, in Thailand, the proportion of dogs testing positive among those examined for rabies averaged 54 percent in a 1998 report, indicating that rabies is still a major public health threat [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/19\">",
"     19",
"    </a>",
"    ]. Furthermore, 42 percent of rabid dogs were less than six months old; this is the age group most likely to interact with humans and the group least likely to have received rabies vaccination. Thus, postexposure treatment is recommended following all potential exposures and prophylaxis should be considered by travelers spending significant periods of time in the region.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Leptospirosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission of leptospirosis to humans usually occurs by either direct or indirect contact of mucous membranes or breaks in the skin with infected water surfaces or animals [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/20\">",
"     20",
"    </a>",
"    ]. Various animals serve as reservoirs, although rats are probably the most important in tropical areas such as Southeast Asia, where the disease is endemic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43879?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although tuberculosis is relatively common in some parts of Southeast Asia, short-term travelers from countries of low endemicity are generally not considered at increased risk of infection, and specific preventative measures are not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Other viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;A recent outbreak of enterovirus 71 infections in Malaysia was associated with encephalomyelitis and the deaths of several children under the age of five years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/21\">",
"     21",
"    </a>",
"    ]. There is also evidence of a new member of the Paramyxoviridae family (Nipah virus) in Malaysia that has been isolated from the cerebrospinal fluid of several patients with encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25622?source=see_link\">",
"     \"Nipah and Hendra viral encephalitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     OTHER HAZARDS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Motor vehicle accidents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury caused by motor vehicles is one of the greatest health hazards and a leading cause of death in travelers, although data specific to travelers to Southeast Asia is lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Snake bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venomous snakes are present throughout Southeast Asia. The Malayan pit viper (Calloselasma rhodostoma), Russell's viper (Daboia russelii), green pit vipers (eg, Trimeresurus albolabris), and the monocellate cobra (Naja kaouthia) are responsible for most bites and deaths. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31431?source=see_link\">",
"     \"Principles of snake bite management worldwide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Marine hazards",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many potential marine hazards in the waters around Southeast Asia. Envenomation by marine creatures (including jellyfish, sea snakes, blue-ringed octopus, cone shells, stingrays, and stone fish) accounts for many fatalities and severe morbidity in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12568/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     High altitude disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several mountainous regions in Southeast Asia at altitudes over 2500 m in which acute mountain sickness is possible (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\"",
"    </a>",
"    ). Carstensz Pyramid (5030 m) in Irian Jaya is the region's highest point, but the most likely places for high altitude exposure are volcanoes in other parts of Indonesia, and Kinabalu (4094 m) in Malaysia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/44/21187?source=see_link\">",
"       \"Patient information: Vaccines for travel (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link\">",
"       \"Patient information: General travel advice (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H936405\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Southeast Asia encompasses the region from southern China through the Indochina peninsula and islands bordering the South China Sea to the island of New Guinea. The countries within this region are Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar (Burma), the Philippines, Singapore, Thailand, and Vietnam. The health risks vary considerably from region to region within Southeast Asia, although there are only a few places (eg, Singapore) where the risks do not differ appreciably from western Europe, North America, and Australia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a GeoSentinel report, the following observations were noted in nearly 3000 ill travelers who had returned from Southeast Asia:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Most patients (72 percent) presented within one month after returning from travel, and 11 percent required hospitalization.",
"     </li>",
"     <li>",
"      The primary manifestations in over 60 percent of returned travelers fell into four major syndrome categories: systemic febrile illness without localizing findings, acute diarrhea, dermatologic disorders, and nondiarrheal gastrointestinal disorders.",
"     </li>",
"     <li>",
"      Among patients with a systemic febrile illness, 32 percent had dengue, 13 percent had malaria, 3 percent had mononucleosis (due to Epstein-Barr virus or cytomegalovirus), 3 percent had Salmonella typhi or S. paratyphi infection, 2 percent had a rickettsial infection, and no cause was reported in 45 percent.",
"     </li>",
"     <li>",
"      Among patients with acute diarrhea, 36 percent had bacterial infection (mostly Campylobacter and nontyphoidal salmonella), 24 percent had parasitic infection (mostly giardiasis and amebiasis), a small number had viral infection, and 36 percent had unspecified acute diarrhea. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Surveillance data'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malaria endemic areas exist in all countries in Southeast Asia except Singapore and Brunei. Within endemic areas, transmission occurs year round. Country-specific risk areas are discussed above. Drug-resistant malaria has been a major problem in Southeast Asia, with chloroquine-resistant Plasmodium falciparum predominating in virtually all endemic areas.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"       Mefloquine",
"      </a>",
"      resistance occurs in the Thai-Myanmar and Thai-Cambodian border regions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Malaria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other arthropod-borne diseases that are endemic in Southeast Asia include Japanese encephalitis, dengue, and typhus. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Arthropod-borne diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Southeast Asia (with the exception of Singapore) is regarded as a high risk area for the development of travelers' diarrhea. The most commonly isolated pathogens are similar to other high risk areas of the world with the possible exception of Vibrio parahaemolyticus, which is more common in the region and is associated with seafood ingestion. In Thailand, enteric pathogens have developed resistance to most classes of antibiotics used to treat diarrhea, including the newer fluoroquinolones and macrolides. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Travelers' diarrhea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other foodborne and waterborne diseases in Southeast Asia include cholera, typhoid, hepatitis A, and hepatitis E. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Foodborne and waterborne diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other infections that travelers in Southeast Asia may be exposed to include avian influenza, HIV, hepatitis B, other sexually transmitted diseases, hepatitis C, melioidosis, penicilliosis, rabies, and leptospirosis. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Other infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other hazards for travelers include motor vehicle accidents, snake bites, envenomation by marine creatures, and high altitude disease. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Other hazards'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/1\">",
"      Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006; 354:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/2\">",
"      Wilson ME, Weld LH, Boggild A, et al. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007; 44:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/3\">",
"      Strickman D, Tanskul P, Eamsila C, Kelly DJ. Prevalence of antibodies to rickettsiae in the human population of suburban Bangkok. Am J Trop Med Hyg 1994; 51:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/4\">",
"      Parola P, Vogelaers D, Roure C, et al. Murine typhus in travelers returning from Indonesia. Emerg Infect Dis 1998; 4:677.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. International Travel and Health. Geneva, WHO 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/6\">",
"      Steffen R. Epidemiologic studies of travelers' diarrhea, severe gastrointestinal infections, and cholera. Rev Infect Dis 1986; 8 Suppl 2:S122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/7\">",
"      Taylor DN, Echeverria P. Etiology and epidemiology of travelers' diarrhea in Asia. Rev Infect Dis 1986; 8 Suppl 2:S136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/8\">",
"      Hoge CW, Gambel JM, Srijan A, et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/9\">",
"      Corwin AL, Khiem HB, Clayson ET, et al. A waterborne outbreak of hepatitis E virus transmission in southwestern Vietnam. Am J Trop Med Hyg 1996; 54:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/10\">",
"      Corwin A, Jarot K, Lubis I, et al. Two years' investigation of epidemic hepatitis E virus transmission in West Kalimantan (Borneo), Indonesia. Trans R Soc Trop Med Hyg 1995; 89:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/11\">",
"      Poovorawan Y, Theamboonlers A, Chumdermpadetsuk S, Komolmit P. Prevalence of hepatitis E virus infection in Thailand. Ann Trop Med Parasitol 1996; 90:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/12\">",
"      Chow WC, Ng HS, Lim GK, Oon CJ. Hepatitis E in Singapore--a seroprevalence study. Singapore Med J 1996; 37:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/13\">",
"      Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353:1374.",
"     </a>",
"    </li>",
"    <li>",
"     Emerg Infect Dis 2004; 10(2) [whole issue devoted to SARS].",
"    </li>",
"    <li>",
"     UNAIDS/WHO epidemiological fact sheets on HIV/AIDS and sexually transmitted diseases. Geneva: UNAIDS/WHO 2002. Available at: www.who.int/emc-hiv/fact_sheets/index.html (Accessed on March 08, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/16\">",
"      Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/17\">",
"      Sauerwein RW, Lammers JW, Horrevorts AM. Ceftazidime monotherapy for pulmonary melioidosis in a traveler returning from Thailand. Chest 1992; 101:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/18\">",
"      Duong TA. Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin Infect Dis 1996; 23:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/19\">",
"      Mitmoonpitak C, Tepsumethanon V, Wilde H. Rabies in Thailand. Epidemiol Infect 1998; 120:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/20\">",
"      Antony SJ. Leptospirosis - An Emerging Pathogen in Travel Medicine: A Review of its Clinical Manifestations and Management. J Travel Med 1996; 3:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/21\">",
"      Uppal PK. Emergence of Nipah virus in Malaysia. Ann N Y Acad Sci 2000; 916:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/22\">",
"      Chan LG, Parashar UD, Lye MS, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis 2000; 31:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/23\">",
"      Fenner PJ. Dangers in the ocean: the traveler and marine envenomation. I. jellyfish. J Travel Med 1998; 5:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12568/abstract/24\">",
"      Fenner PJ. Dangers in the ocean: the traveler and marine envenomation. II. Marine vertebrates. J Travel Med 1998; 5:213.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3886 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-71122602D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_17_12568=[""].join("\n");
var outline_f12_17_12568=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H936405\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SURVEILLANCE DATA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ARTHROPOD-BORNE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Malaria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Drug-resistant malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Japanese encephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dengue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Typhus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Yellow fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chikungunya fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FOODBORNE AND WATERBORNE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Travelers' diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cholera",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Typhoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hepatitis A and hepatitis E",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Poliomyelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Schistosomiasis and other fluke infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OTHER INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Avian influenza",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Severe acute respiratory syndrome (SARS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other sexually transmitted diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Hepatitis B and hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Melioidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Penicillium marneffei infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Plague",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Rabies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Leptospirosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Other viral infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      OTHER HAZARDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Motor vehicle accidents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Snake bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Marine hazards",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      High altitude disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H936405\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15576?source=related_link\">",
"      Chikungunya fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18554?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11512?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7398?source=related_link\">",
"      Diagnosis of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33302?source=related_link\">",
"      Epidemiology and clinical manifestations of Penicillium marneffei infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4984?source=related_link\">",
"      Epidemiology of dengue virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24774?source=related_link\">",
"      Epidemiology, microbiology and pathogenesis of plague (Yersinia pestis infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39577?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations, and diagnosis of melioidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14090?source=related_link\">",
"      Epidemiology, transmission, and pathogenesis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39304?source=related_link\">",
"      Evaluation of fever in the returning traveler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33976?source=related_link\">",
"      Hepatitis E virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=related_link\">",
"      High altitude illness: Physiology, risk factors, and general prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5208?source=related_link\">",
"      Japanese encephalitis: Epidemiology, diagnosis, treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43879?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25622?source=related_link\">",
"      Nipah and Hendra viral encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=related_link\">",
"      Overview of Vibrio cholerae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=related_link\">",
"      Overview of hepatitis A virus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29768?source=related_link\">",
"      Pathogenesis of Vibrio cholerae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/44/21187?source=related_link\">",
"      Patient information: Vaccines for travel (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36553?source=related_link\">",
"      Polio and infectious diseases of the anterior horn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=related_link\">",
"      Prevention of malaria infection in travelers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31431?source=related_link\">",
"      Principles of snake bite management worldwide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26852?source=related_link\">",
"      Scrub typhus: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17753?source=related_link\">",
"      Severe acute respiratory syndrome (SARS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27796?source=related_link\">",
"      The epidemiology and clinical manifestations of murine typhus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=related_link\">",
"      The global human immunodeficiency virus pandemic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29145?source=related_link\">",
"      Travelers' diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/21/15705?source=related_link\">",
"      Yellow fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_17_12569="Evaluation of dysphagia in adults";
var content_f12_17_12569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of dysphagia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/17/12569/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/17/12569/contributors\">",
"     Ronnie Fass, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/17/12569/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/17/12569/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/17/12569/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/17/12569/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/17/12569/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The word dysphagia is derived from the Greek words \"dys\" (with difficulty) and \"phagia\" (to eat). Dysphagia is a subjective sensation that suggests the presence of an organic abnormality in the passage of liquids or solids from the oral cavity to the stomach. Patients' complaints range from the inability to initiate a swallow to the sensation of solids or liquids being hindered during their passage through the esophagus into the stomach. The term \"odynophagia\" refers to pain with swallowing.",
"   </p>",
"   <p>",
"    Dysphagia is considered to be an alarm symptom, indicating the need for an immediate evaluation to define the exact cause and initiate appropriate therapy. Dysphagia in elderly subjects should",
"    <strong>",
"     not",
"    </strong>",
"    be attributed to normal aging. Aging alone causes mild esophageal motility abnormalities, which are rarely symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dysphagia can be classified as either oropharyngeal or esophageal:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oropharyngeal dysphagia, also called transfer dysphagia, arises from disorders that affect the function of the oropharynx, larynx, and upper esophageal sphincter. Neurogenic and myogenic disorders as well as oropharyngeal tumors are the most common underlying mechanisms for oropharyngeal dysphagia.",
"     </li>",
"     <li>",
"      Esophageal dysphagia arises within the body of the esophagus, the lower esophageal sphincter, or cardia, and is most commonly due to mechanical causes or a motility disturbance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some patients no cause can be identified; these patients have been categorized as having functional dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral dysfunction can lead to drooling, food spillage, sialorrhea, difficulty initiating a swallow, piecemeal swallows, and dysarthria. Pharyngeal dysfunction can lead to a sensation of \"food getting stuck\" immediately upon swallowing, postnasal regurgitation, coughing or choking during food consumption, and dysphonia. In addition, patients with oropharyngeal dysphagia point toward the cervical region when asked to identify the site of their symptoms. In contrast, patients with esophageal dysphagia usually describe the onset of symptoms several seconds after initiating a swallow. They frequently point to the suprasternal notch or behind the sternum when asked to localize the area causing symptoms. Retrosternal dysphagia usually corresponds with the location of the lesion, while suprasternal dysphagia is commonly referred from below [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will focus on esophageal dysphagia; oropharyngeal dysphagia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2037?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of oropharyngeal dysphagia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=see_link\">",
"     \"Diagnosis and treatment of oropharyngeal dysphagia\"",
"    </a>",
"    .) The AGA guideline for oropharyngeal dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/4\">",
"     4",
"    </a>",
"    ] and for benign causes of esophageal dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/5\">",
"     5",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEDICAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cornerstone of evaluation of patients with dysphagia is a careful history (",
"    <a class=\"graphic graphic_table graphicRef68343 \" href=\"UTD.htm?1/49/1820\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/6\">",
"     6",
"    </a>",
"    ]. Understanding the different mechanisms that can lead to dysphagia can help to direct questions that can determine the cause and subsequent course of action (",
"    <a class=\"graphic graphic_algorithm graphicRef70866 \" href=\"UTD.htm?31/33/32287\">",
"     algorithm 1",
"    </a>",
"    ). The history can also help distinguish dysphagia from odynophagia and globus sensation (a feeling of a lump in the throat) for which the differential diagnosis and evaluation may be different. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/19/21814?source=see_link\">",
"     \"Globus sensation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A critical component of the medical history is determining the types of food that produce symptoms (solids, liquids, or both) and the temporal progression of symptoms. Dysphagia to both solids and liquids from the onset of symptoms is probably due to a motility disorder of the esophagus. In contrast, dysphagia for solids that later progresses to involve liquids is more likely to reflect mechanical obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Determining whether symptoms are progressive or",
"    <span class=\"nowrap\">",
"     intermittent/nonprogressive",
"    </span>",
"    can also be helpful. Progressive dysphagia is usually caused by cancer or a peptic stricture, while intermittent dysphagia is most often related to a lower esophageal ring (see appropriate topic reviews). However, patients with motility disorders may also exhibit progressive dysphagia (usually those with achalasia or scleroderma) or may exhibit",
"    <span class=\"nowrap\">",
"     intermittent/nonprogressive",
"    </span>",
"    dysphagia (usually those with hypertensive lower esophageal sphincter, diffuse esophageal spasm, or nonspecific motility disorders).",
"   </p>",
"   <p>",
"    Symptoms or findings such as heartburn, weight loss, hematemesis, coffee ground emesis, anemia, regurgitation of food particles, and respiratory symptoms can further help to narrow the differential diagnosis (",
"    <a class=\"graphic graphic_algorithm graphicRef81108 \" href=\"UTD.htm?16/8/16527\">",
"     algorithm 2",
"    </a>",
"    ). As an example, chronic heartburn in a patient with dysphagia may be a clue to the presence of complications of gastroesophageal reflux disease, such as erosive esophagitis, peptic stricture, and adenocarcinoma of the esophagus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19253?source=see_link\">",
"     \"Complications of gastroesophageal reflux in adults\"",
"    </a>",
"    .) However, the absence of heartburn does not rule out reflux-related complications since approximately one-fourth of patients with peptic stricture and at least one-third of those with adenocarcinoma of the esophagus had no heartburn prior to diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Furthermore, more than 40 percent of the patients with achalasia complain of heartburn, although its cause remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of conditions are associated with esophageal dysphagia, the most common of which will be reviewed here (",
"    <a class=\"graphic graphic_table graphicRef80528 \" href=\"UTD.htm?13/20/13644\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Peptic stricture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peptic stricture is a complication of acid reflux, which occurs in approximately 10 percent of patients with gastroesophageal reflux disease (GERD) who seek medical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The development of peptic strictures among patients with reflux has been associated with older age, male gender, and longer duration of reflux symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition to GERD, peptic strictures have been observed in a number of other conditions that lead to increased esophageal acid exposure. Examples include scleroderma, Zollinger-Ellison syndrome, nasogastric tube placement, and Heller myotomy for achalasia. Patients with a variety of other disorders, such as infectious esophagitis, post surgical resection for esophageal or laryngeal cancer, caustic ingestion, pill esophagitis, and radiation exposure, may develop narrowing of the esophagus that is similar to a peptic stricture despite its nonpeptic origin.",
"   </p>",
"   <p>",
"    Symptoms of peptic strictures are usually insidious but progressive beginning with dysphagia to solids followed by dysphagia to liquids [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/14\">",
"     14",
"    </a>",
"    ]. Symptoms correspond to the caliber of the stricture; dysphagia to solids is usually present when the esophageal lumen is narrowed to 13 mm or less. Some patients adapt to progression of the stricture by adopting a softer or even liquid diet [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition to dysphagia, patients with GERD may have a variety of other symptoms suggesting a diagnosis such as heartburn and acid regurgitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Eosinophilic esophagitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic esophagitis has emerged as an important cause of dysphagia, particularly in adolescents and young adults with environmental allergies and a history of food impaction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/15\">",
"     15",
"    </a>",
"    ]. Adults commonly demonstrate esophageal narrowing, multiple rings, furrows, and occasionally numerous small abscesses of eosinophils. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Esophageal webs and rings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal webs and rings are thin, fragile strictures that partially or completely compromise the esophageal lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/16\">",
"     16",
"    </a>",
"    ]. They can be solitary or multiple. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12838?source=see_link\">",
"     \"Esophageal webs and rings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term web refers to a thin mucosal fold that protrudes into the lumen and is covered with squamous epithelium. Webs most commonly occur anteriorly in the cervical esophagus, causing focal narrowing in the postcricoid area (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef76514 \" href=\"UTD.htm?2/35/2623\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Esophageal rings were described by Schatzki as mucosal structures at the gastroesophageal junction that are smooth, thin (&lt;4 mm in axial length), and covered with squamous mucosa above and columnar epithelium below (",
"      <a class=\"graphic graphic_picture graphicRef55092 \" href=\"UTD.htm?29/40/30351\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68185 \" href=\"UTD.htm?41/36/42574\">",
"       image 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Rings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of esophageal rings is unclear, although GERD has been implicated at least in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/18\">",
"     18",
"    </a>",
"    ]. In comparison to mucosal rings, muscular rings are rare, usually seen in children, located within 2 cm of the squamocolumnar junction, and characterized by hypertrophic musculature in the esophageal body. The presence of multiple rings should raise suspicion for eosinophilic esophagitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The caliber of a muscular ring changes during peristalsis, distinguishing it from a peptic stricture or mucosal ring. On",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow and upper endoscopy they appear as a focal, thick constriction of variable luminal diameter located a few centimeters above the squamo-columnar junction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with esophageal rings usually have intermittent dysphagia for solids, particularly when the ring diameter narrows to 13 mm or less [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/17\">",
"     17",
"    </a>",
"    ]. The sensation is usually short-lived, associated with chest discomfort, and relieved by regurgitating the food bolus, drinking liquids, or positional changes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/20\">",
"     20",
"    </a>",
"    ]. Some patients present with acute dysphagia after swallowing a large piece of meat (termed the \"steak house\" syndrome) that requires immediate endoscopic intervention to remove the food bolus. Patients with esophageal rings may learn to carefully chew their food and follow solid food swallowing with large amounts of liquid to avoid food impaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Webs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with esophageal webs are often asymptomatic or have only intermittent dysphagia; the web is frequently discovered incidentally during radiographic studies for other reasons. However, esophageal rings have been described in association with iron deficiency (the Plummer-Vinson or Paterson-Kelly syndrome) in which case anemia, koilonychia, or other manifestations of iron deficiency may be present (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81131 \" href=\"UTD.htm?36/35/37438\">",
"     image 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer of the esophagus or gastric cardia is often associated with anorexia, significant weight loss, and rapidly progressive dysphagia, initially for solids and later for liquids. In addition, such patients frequently have chest pain, odynophagia, and anemia. An achalasia-like syndrome (pseudoachalasia) has been described in patients with adenocarcinoma of the cardia due to microscopic infiltration of the myenteric plexus or the vagus nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients are usually older than 60, have had symptoms for less than one year, and report a significant weight loss (&gt;10 kg) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link\">",
"     \"Clinical manifestations and diagnosis of achalasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two main histologic types of esophageal carcinoma are adenocarcinoma and squamous cell carcinoma, which have similar clinical presentations despite their different epidemiology. Squamous cell carcinoma is associated with tobacco and alcohol abuse, is common in Asia (particularly China and Singapore), and demonstrates a predilection to African Americans in the United States. In contrast, adenocarcinoma occurs mainly in Caucasian males in their 60s who have a long history of GERD and underlying Barrett's mucosa (",
"    <a class=\"graphic graphic_picture graphicRef50584 \" href=\"UTD.htm?28/18/28961\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The incidence of adenocarcinoma of the esophagus and cardia is among the most rapidly increasing of all cancers in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=see_link\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cardiovascular abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of vascular anomalies can cause dysphagia by compressing the esophagus (\"dysphagia lusoria\"). Some of the aberrant vessels form complete rings, while others form incomplete rings around the esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=see_link\">",
"     \"Vascular rings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete vascular ring anomalies include a double aortic arch, right aortic arch with retroesophageal left subclavian artery and left ligamentum arteriosum, and right aortic arch with mirror-image branching and left ligamentum arteriosum [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/28\">",
"       28",
"      </a>",
"      ]. The prevalence of the former has been suggested to be 0.36 percent and accurate diagnosis can be achieved by endoscopic ultrasonography [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Incomplete vascular ring anomalies include retroesophageal right aberrant subclavian artery and anomalous left pulmonary artery [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the elderly, severe atherosclerosis or a large aneurysm of the thoracic aorta can result in impingement on the esophagus and produce dysphagia (\"dysphagia aortica\").",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When symptoms are intractable, surgical intervention should be considered. When due to congenital causes, symptoms usually develop during childhood, but they may also develop in adults.",
"   </p>",
"   <p>",
"    Most subjects with an aberrant subclavian artery are symptom free throughout their lives [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/30\">",
"     30",
"    </a>",
"    ]. However, coughing, dysphagia, thoracic pain, or even Horner's syndrome may develop at an older age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/31\">",
"     31",
"    </a>",
"    ]. In infants, there is an increase in pulmonary infections and respiratory abnormalities.",
"   </p>",
"   <p>",
"    Enlargement of the left atrium may cause dysphagia in patients with mitral valve disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/32\">",
"     32",
"    </a>",
"    ]. This is due to extrinsic compression by the enlarged atrium, resulting in partial luminal obstruction at the mid to lower third portion of the esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radiation injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing palliative or radical radiotherapy for thoracic or head and neck tumors are at risk for developing esophagitis and esophageal strictures. In the acute setting, patients may develop esophagitis resulting in dysphagia and odynophagia. In some patients, chronic radiation esophagitis develops, which may present as esophageal ulcerations or strictures resulting from chronic ischemia and radiation fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=see_link&amp;anchor=H14#H14\">",
"     \"Gastrointestinal toxicity of radiation therapy\", section on 'Radiation enteritis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The location of the strictures depends upon the site of maximal radiation injury. As a result, proximal strictures are more common in patients receiving radiation for head and neck cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another potential cause of dysphagia in patients who have received thoracic radiation is a motility disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/35\">",
"     35",
"    </a>",
"    ]. However, one report demonstrated that radiotherapy had only a minimal effect on esophageal motility or transit [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Achalasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Achalasia (a Greek term that means \"does not relax\") is a disease of unknown cause in which there is a loss of peristalsis in the distal esophagus (whose musculature is comprised entirely of smooth muscle) and a failure of LES relaxation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43124?source=see_link\">",
"     \"Pathophysiology and etiology of achalasia\"",
"    </a>",
"    .) Although both of these abnormalities impair esophageal emptying, the symptoms and signs of achalasia are due primarily to the defect in LES relaxation. The relentless LES contraction causes functional obstruction of the esophagus that persists until the hydrostatic pressure of the retained material exceeds the pressure generated by the sphincter muscle (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54252 \" href=\"UTD.htm?19/35/20016\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53672 \" href=\"UTD.htm?23/55/24446\">",
"     image 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Achalasia is an uncommon disorder that has an annual incidence of approximately 1 case per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/37\">",
"     37",
"    </a>",
"    ]. Men and women are affected with equal frequency. The disease can occur at virtually any age, but onset before adolescence is unusual. Achalasia is typically diagnosed in patients who are between the ages of 25 and 60 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link\">",
"     \"Clinical manifestations and diagnosis of achalasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dysphagia for solids (91 percent) and liquids (85 percent) is the primary clinical feature of achalasia. Although dysphagia for liquids can occur in patients with other esophageal motility disorders (eg, scleroderma), it is most characteristic of achalasia and strongly suggests the diagnosis.",
"   </p>",
"   <p>",
"    Patients with achalasia may have a number of other clinical features, including weight loss, chronic cough, chest pain, hiccups, regurgitation, heartburn, and globus sensation. In addition, an association with adrenal insufficiency and alacrima (triple A syndrome or Allgrove syndrome) has been described in children with achalasia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/38\">",
"     38",
"    </a>",
"    ]. It is possible that a variant of this syndrome is present in adults since, in one report, 4 of 20 adults with achalasia had deficient tear production [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/39\">",
"     39",
"    </a>",
"    ]. Hiccups are common in patients with achalasia and probably result from functional obstruction of the distal esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with Chagas disease may have clinical features similar to achalasia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66813 \" href=\"UTD.htm?38/9/39070\">",
"     image 6",
"    </a>",
"    ). Dysphagia develops weeks up to years after contracting Trypanosoma cruzi. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19975?source=see_link\">",
"     \"Pathology and pathogenesis of Chagas disease\"",
"    </a>",
"    .) Patients with a nondilated esophagus usually have mild, intermittent dysphagia, while those with megaesophagus experience constant dysphagia for solids and occasionally for liquids [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/41\">",
"     41",
"    </a>",
"    ]. Other symptoms similar to achalasia may also be present, including regurgitation of food particles, hiccups, chronic cough, chest pain, and weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Spastic motility disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse esophageal spasm (DES), nutcracker esophagus, hypertensive lower esophageal sphincter, and other nonspecific spastic esophageal motility disorders can cause dysphagia to solids and liquids.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DES is probably caused by a combination of muscular and neural defects, which can be provoked by a number of stimuli such as acid reflux, stress, hot or cold food, carbonated beverages, and certain smells (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69821 \" href=\"UTD.htm?26/30/27118\">",
"       image 7",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13096?source=see_link\">",
"       \"Diffuse esophageal spasm, nutcracker esophagus, and hypertensive lower esophageal sphincter\"",
"      </a>",
"      .) Patients with DES experience intermittent dysphagia, the severity of which is variable; other symptoms include chest pain and heartburn. Patients with esophageal contractions &lt;74 mmHg in amplitude tend to report less chest pain than those with contractions &gt;100 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dysphagia and chest pain are also frequent in patients with nutcracker esophagus, hypertensive lower esophageal sphincter, and a variety of other spastic disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13096?source=see_link\">",
"       \"Diffuse esophageal spasm, nutcracker esophagus, and hypertensive lower esophageal sphincter\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ineffective esophageal motility disorder (IEMD), defined as at least 30 percent of the distal esophageal amplitude contractions below 30 mmHg, has been associated with dysphagia. Approximately 30 percent of subjects with IEMD reported dysphagia in one report. However, studies using esophageal intraluminal impedance testing have shown that up to 68 percent of liquid and 59 percent of viscous swallows in such patients showed normal bolus transit [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/44\">",
"       44",
"      </a>",
"      ]. Overall one-third of patients had normal bolus transit suggesting that the manometric diagnosis of IEMD does not always correlate with the effectiveness of esophageal function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Scleroderma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal involvement is present in up to 90 percent of patients with scleroderma regardless of whether or not they have CREST syndrome or diffuse scleroderma (",
"    <a class=\"graphic graphic_table graphicRef55280 \" href=\"UTD.htm?2/35/2621\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=see_link\">",
"     \"Gastrointestinal manifestations of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .) Scleroderma primarily involves the smooth muscle layer of the gut wall, resulting in atrophy and sclerosis of the distal two-thirds of the esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/45\">",
"     45",
"    </a>",
"    ]. As a result, the most common motility abnormalities observed in the distal two-thirds of the esophagus are aperistalsis or low amplitude contractions, and low or absent lower esophageal sphincter pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/48\">",
"     48",
"    </a>",
"    ]. The proximal esophagus (striated muscle) is spared and exhibits normal motility.",
"   </p>",
"   <p>",
"    Patients with scleroderma involving the esophagus are at increased risk for developing severe gastroesophageal reflux disease, leading to the common complaints of chronic heartburn [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/49\">",
"     49",
"    </a>",
"    ]. Progressive dysphagia to both solids and liquids may develop secondary to motility abnormality or may suggest the presence of peptic stricture, which occurs in up to 50 percent of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Sj&ouml;gren's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sj&ouml;gren's syndrome is also commonly associated with dysphagia. In one series, for example, up to 74 percent of patients complained of dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/51\">",
"     51",
"    </a>",
"    ]. Xerostomia exacerbated swallowing discomfort but did not appear to correlate with dysphagia. In most patients, no other obvious cause for dysphagia was documented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609924103\">",
"    <span class=\"h2\">",
"     Lymphocytic esophagitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocytic esophagitis is characterized by the presence of a dense peripapillary lymphocytic infiltrate and peripapillary spongiosis involving the lower two-thirds of the esophageal epithelium and the absence of significant neutrophilic or eosinophilic infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/52\">",
"     52",
"    </a>",
"    ]. While lymphocytic esophagitis is being increasingly recognized on histopathology in adults, it is unclear if it is a distinct clinical entity and its etiology is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one retrospective study of 129,252 adults who had undergone an upper endoscopy, 0.1 percent had lymphocytic esophagitis on biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/53\">",
"     53",
"    </a>",
"    ]. As compared with patients with normal esophageal biopsies, patients with lymphocytic esophagitis were significantly more likely to be older (63 versus 55 years) and to have presented with dysphagia (53 versus 33 percent), and were significantly less likely to have GERD (19 versus 38 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Functional dysphagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional dysphagia is a diagnosis of exclusion in patients with dysphagia who have undergone a complete diagnostic evaluation without evidence of a structural abnormality or motility disturbance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/2\">",
"     2",
"    </a>",
"    ]. Recommended diagnostic criteria :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least 12 weeks of a sense of solid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      liquid foods sticking, lodging, or passing abnormally through the esophagus, with symptom onset at least six months prior to diagnosis.",
"     </li>",
"     <li>",
"      The absence of gastroesophageal reflux and motility disorders such as scleroderma and achalasia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms of dysphagia may be intermittent or present after each meal, and may be indistinguishable from dysphagia caused by mechanical or motility disorders. These patients pose a therapeutic dilemma since management options are limited. Studies assessing the epidemiology, etiology, and therapy of this condition are scarce. However, it is our impression that symptoms improve with time. Patients should be reassured and instructed to avoid precipitating factors and chew well. In patients with severe symptoms despite the above, treatment with a calcium channel blocker, anticholinergic agent, antidepressant, anxiolytic, or smooth-muscle relaxant can be considered. Some endoscopists perform empiric esophageal dilation with a 50 to 54 F Maloney dilator, a practice that was supported in at least one controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/56\">",
"     56",
"    </a>",
"    ], but found to be ineffective in another [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SPECIFIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial testing in patients with dysphagia should be based upon the medical history (",
"    <a class=\"graphic graphic_algorithm graphicRef81108 \" href=\"UTD.htm?16/8/16527\">",
"     algorithm 2",
"    </a>",
"    ). Patients with dysphagia usually require early referral since most will need an endoscopy. Patients with a history or clinical features suggesting a proximal esophageal lesion (eg, surgery for laryngeal or esophageal cancer, Zenker's diverticulum, or radiation therapy), a complex (tortuous) stricture (eg, history of caustic injury or radiation therapy), or achalasia should be evaluated initially with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/5\">",
"     5",
"    </a>",
"    ]. In these patients, a barium swallow may be a more sensitive test and potentially safer than upper endoscopy; intubation of the proximal esophagus during endoscopy is done relatively blindly, thereby risking perforation in patients with upper esophageal pathology. In other patients, proceeding directly with an upper endoscopy is a reasonable option [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/58\">",
"     58",
"    </a>",
"    ]. In addition to its diagnostic value, endoscopy offers an opportunity to obtain tissue samples and to perform a therapeutic intervention.",
"   </p>",
"   <p>",
"    Lower esophageal rings or extrinsic esophageal compression can be overlooked during upper endoscopy. A radiographic evaluation using the full column technique can be helpful if mechanical obstruction is suspected despite a negative upper endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/59\">",
"     59",
"    </a>",
"    ]. Patients should be instructed to drink",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    in the prone-oblique position; maximal distension of the esophagogastric junction is achieved by having the patient swallow barium rapidly in association with different respiratory movements [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/60\">",
"     60",
"    </a>",
"    ]. In addition, asking the patient to swallow 13 mm barium tablets or a solid bolus, such as a marshmallow or bread, may be helpful for demonstrating subtle lesions in patients with persistent or intermittent solid food dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A motility abnormality should be suspected in patients in whom the above testing is unrevealing. A motility disorder (mostly nonspecific or achalasia) has been detected in up to 50 percent of patients with nonstructural dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. The gold standard for the diagnosis of motility disorders is an esophageal motility study. However, certain motility disorders (such as achalasia) can be strongly suspected based upon their characteristic radiographic appearance when in advanced stages (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54252 \" href=\"UTD.htm?19/35/20016\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53672 \" href=\"UTD.htm?23/55/24446\">",
"     image 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/5,59,65\">",
"     5,59,65",
"    </a>",
"    ]. Nevertheless, confirmation with a motility study is usually required [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16568?source=see_link\">",
"     \"Motility testing: When does it help?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Acute dysphagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present with acute dysphagia require immediate evaluation and intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/67\">",
"     67",
"    </a>",
"    ]. The estimated annual incidence is 13.0 per 100,000 and the male to female ratio is 1.7:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/68\">",
"     68",
"    </a>",
"    ]. The rate increases with age, especially after the seventh decade. The patients commonly have an underlying component of mechanical obstruction that has been medically managed previously or was never brought to the attention of a physician.",
"   </p>",
"   <p>",
"    Food impaction is by far the most common cause for acute dysphagia in adults. Patients usually develop symptoms after ingesting meat (most commonly beef, chicken, and turkey) which completely obstructs the esophageal lumen, resulting in expectoration of saliva [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/69\">",
"     69",
"    </a>",
"    ]. Removal of the food bolus either by pushing it further down to the stomach or pulling it out results in dramatic improvement. The push technique is safe and effective in the treatment of most patients with food impaction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12569/abstract/68,70\">",
"     68,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/13/7378?source=see_link\">",
"       \"Patient information: Dysphagia (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/19/10546?source=see_link\">",
"       \"Patient information: Esophageal stricture (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dysphagia is considered to be an alarm symptom, indicating the need for an immediate evaluation to define the exact cause and initiate appropriate therapy (",
"      <a class=\"graphic graphic_algorithm graphicRef70866 \" href=\"UTD.htm?31/33/32287\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef81108 \" href=\"UTD.htm?16/8/16527\">",
"       algorithm 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      It can be classified as either oropharyngeal or esophageal (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above). An approach to patients with oropharyngeal dysphagia is presented separately (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=see_link\">",
"       \"Diagnosis and treatment of oropharyngeal dysphagia\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The cornerstone of evaluation is a careful history (",
"      <a class=\"graphic graphic_table graphicRef68343 \" href=\"UTD.htm?1/49/1820\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Medical history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A large number of conditions are associated with esophageal dysphagia (",
"      <a class=\"graphic graphic_table graphicRef80528 \" href=\"UTD.htm?13/20/13644\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial testing for esophageal dysphagia should be based upon the medical history (",
"      <a class=\"graphic graphic_algorithm graphicRef81108 \" href=\"UTD.htm?16/8/16527\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Specific testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/1\">",
"      Shamburek RD, Farrar JT. Disorders of the digestive system in the elderly. N Engl J Med 1990; 322:438.",
"     </a>",
"    </li>",
"    <li>",
"     Drossman DA. Rome III: The Functional Gastrointestinal Disorder, 3rd ed, Degnon Associates, Inc, McLean, VA 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/3\">",
"      Wilcox CM, Alexander LN, Clark WS. Localization of an obstructing esophageal lesion. Is the patient accurate? Dig Dis Sci 1995; 40:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/4\">",
"      American Gastroenterological Association medical position statement on management of oropharyngeal dysphagia. Gastroenterology 1999; 116:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/5\">",
"      Spechler SJ. American gastroenterological association medical position statement on treatment of patients with dysphagia caused by benign disorders of the distal esophagus. Gastroenterology 1999; 117:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/6\">",
"      Trate DM, Parkman HP, Fisher RS. Dysphagia. Evaluation, diagnosis, and treatment. Prim Care 1996; 23:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/7\">",
"      Castell DO, Donner MW. Evaluation of dysphagia: a careful history is crucial. Dysphagia 1987; 2:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/8\">",
"      Nayyar AK, Royston C, Bardhan KD. Oesophageal acid-peptic strictures in the histamine H2 receptor antagonist and proton pump inhibitor era. Dig Liver Dis 2003; 35:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/9\">",
"      Lagergren J, Bergstr&ouml;m R, Lindgren A, Nyr&eacute;n O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/10\">",
"      Spechler SJ, Souza RF, Rosenberg SJ, et al. Heartburn in patients with achalasia. Gut 1995; 37:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/11\">",
"      Katz PO, Knuff TE, Benjamin SB, Castell DO. Abnormal esophageal pressures in reflux esophagitis: cause or effect? Am J Gastroenterol 1986; 81:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/12\">",
"      Spechler SJ. AGA technical review on treatment of patients with dysphagia caused by benign disorders of the distal esophagus. Gastroenterology 1999; 117:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/13\">",
"      El-Serag HB, Sonnenberg A. Association of esophagitis and esophageal strictures with diseases treated with nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1997; 92:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/14\">",
"      Marks RD, Richter JE. Peptic strictures of the esophagus. Am J Gastroenterol 1993; 88:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/15\">",
"      Prasad GA, Talley NJ, Romero Y, et al. Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: a prospective study. Am J Gastroenterol 2007; 102:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/16\">",
"      Tobin RW. Esophageal rings, webs, and diverticula. J Clin Gastroenterol 1998; 27:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/17\">",
"      SCHATZKI R. THE LOWER ESOPHAGEAL RING. LONG TERM FOLLOW-UP OF SYMPTOMATIC AND ASYMPTOMATIC RINGS. Am J Roentgenol Radium Ther Nucl Med 1963; 90:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/18\">",
"      Ott DJ, Ledbetter MS, Chen MY, et al. Correlation of lower esophageal mucosal ring and 24-h pH monitoring of the esophagus. Am J Gastroenterol 1996; 91:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/19\">",
"      Hirano I, Gilliam J, Goyal RK. Clinical and manometric features of the lower esophageal muscular ring. Am J Gastroenterol 2000; 95:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/20\">",
"      DeVault KR. Lower esophageal (Schatzki's) ring: pathogenesis, diagnosis and therapy. Dig Dis 1996; 14:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/21\">",
"      Hoffman RM, Jaffe PE. Plummer-Vinson syndrome. A case report and literature review. Arch Intern Med 1995; 155:2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/22\">",
"      DiBaise JK, Quigley EM. Tumor-related dysmotility: gastrointestinal dysmotility syndromes associated with tumors. Dig Dis Sci 1998; 43:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/23\">",
"      Tucker HJ, Snape WJ Jr, Cohen S. Achalasia secondary to carcinoma: manometric and clinical features. Ann Intern Med 1978; 89:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/24\">",
"      Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol 1997; 92:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/25\">",
"      Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/26\">",
"      Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/27\">",
"      Blot WJ, Devesa SS, Fraumeni JF Jr. Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA 1993; 270:1320.",
"     </a>",
"    </li>",
"    <li>",
"     Bennett JR, Castell DO. Overview and symptom assessment. In: The Esophagus, Castell DO, Richter JE (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.33.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/29\">",
"      De Luca L, Bergman JJ, Tytgat GN, Fockens P. EUS imaging of the arteria lusoria: case series and review. Gastrointest Endosc 2000; 52:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/30\">",
"      Molz G, Burri B. Aberrant subclavian artery (arteria lusoria): sex differences in the prevalence of various forms of the malformation. Evaluation of 1378 observations. Virchows Arch A Pathol Anat Histol 1978; 380:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/31\">",
"      Janssen M, Baggen MG, Veen HF, et al. Dysphagia lusoria: clinical aspects, manometric findings, diagnosis, and therapy. Am J Gastroenterol 2000; 95:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/32\">",
"      Cappell MS. Manometric findings in dysphagia secondary to left atrial dilatation. Giant, cyclic midesophageal pressure waves occurring with every heart beat. Dig Dis Sci 1991; 36:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/33\">",
"      Gotsman I, Mogle P, Shapira MY. An unusual cause of dysphagia. Postgrad Med J 1999; 75:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/34\">",
"      Dhir V, Vege SS, Mohandas KM, Desai DC. Dilation of proximal esophageal strictures following therapy for head and neck cancer: experience with Savary Gilliard dilators. J Surg Oncol 1996; 63:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/35\">",
"      Seeman H, Gates JA, Traube M. Esophageal motor dysfunction years after radiation therapy. Dig Dis Sci 1992; 37:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/36\">",
"      Yeoh E, Holloway RH, Russo A, et al. Effects of mediastinal irradiation on oesophageal function. Gut 1996; 38:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/37\">",
"      Howard PJ, Maher L, Pryde A, et al. Five year prospective study of the incidence, clinical features, and diagnosis of achalasia in Edinburgh. Gut 1992; 33:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/38\">",
"      Allgrove J, Clayden GS, Grant DB, Macaulay JC. Familial glucocorticoid deficiency with achalasia of the cardia and deficient tear production. Lancet 1978; 1:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/39\">",
"      Verma S, Brown S, Dakkak M, Bennett JR. Association of adult achalasia and alacrima. Dig Dis Sci 1999; 44:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/40\">",
"      Seeman H, Traube M. Hiccups and achalasia. Ann Intern Med 1991; 115:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/41\">",
"      de Oliveira RB, Troncon LE, Dantas RO, Menghelli UG. Gastrointestinal manifestations of Chagas' disease. Am J Gastroenterol 1998; 93:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/42\">",
"      Clouse RE. Spastic disorders of the esophagus. Gastroenterologist 1997; 5:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/43\">",
"      Allen ML, DiMarino AJ Jr. Manometric diagnosis of diffuse esophageal spasm. Dig Dis Sci 1996; 41:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/44\">",
"      Tutuian R, Castell DO. Clarification of the esophageal function defect in patients with manometric ineffective esophageal motility: studies using combined impedance-manometry. Clin Gastroenterol Hepatol 2004; 2:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/45\">",
"      Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am 1998; 27:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/46\">",
"      Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol 1989; 28:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/47\">",
"      Stampfl D, Denuna S, Varga J, et al. Relations between dysmotility and acid exposure in scleroderma (SSc). Am J Gastroenterol 1990; 85:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/48\">",
"      Yarze JC, Varga J, Stampfl D, et al. Esophageal function in systemic sclerosis: a prospective evaluation of motility and acid reflux in 36 patients. Am J Gastroenterol 1993; 88:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/49\">",
"      Shoenut JP, Wieler JA, Micflikier AB. The extent and pattern of gastro-oesophageal reflux in patients with scleroderma oesophagus: the effect of low-dose omeprazole. Aliment Pharmacol Ther 1993; 7:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/50\">",
"      Zamost BJ, Hirschberg J, Ippoliti AF, et al. Esophagitis in scleroderma. Prevalence and risk factors. Gastroenterology 1987; 92:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/51\">",
"      Anselmino M, Zaninotto G, Costantini M, et al. Esophageal motor function in primary Sj&ouml;gren's syndrome: correlation with dysphagia and xerostomia. Dig Dis Sci 1997; 42:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/52\">",
"      Rubio CA, Sj&ouml;dahl K, Lagergren J. Lymphocytic esophagitis: a histologic subset of chronic esophagitis. Am J Clin Pathol 2006; 125:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/53\">",
"      Haque S, Genta RM. Lymphocytic oesophagitis: clinicopathological aspects of an emerging condition. Gut 2012; 61:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/54\">",
"      Ronkainen J, Walker MM, Aro P, et al. Lymphocytic oesophagitis, a condition in search of a disease? Gut 2012; 61:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/55\">",
"      Cohen S, Saxena A, Waljee AK, et al. Lymphocytic esophagitis: a diagnosis of increasing frequency. J Clin Gastroenterol 2012; 46:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/56\">",
"      Colon VJ, Young MA, Ramirez FC. The short- and long-term efficacy of empirical esophageal dilation in patients with nonobstructive dysphagia: a prospective, randomized study. Am J Gastroenterol 2000; 95:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/57\">",
"      Scolapio JS, Gostout CJ, Schroeder KW, et al. Dysphagia without endoscopically evident disease: to dilate or not? Am J Gastroenterol 2001; 96:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/58\">",
"      Varadarajulu S, Eloubeidi MA, Patel RS, et al. The yield and the predictors of esophageal pathology when upper endoscopy is used for the initial evaluation of dysphagia. Gastrointest Endosc 2005; 61:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/59\">",
"      Ott DJ. Radiographic techniques and efficacy in evaluating esophageal dysphagia. Dysphagia 1990; 5:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/60\">",
"      Chen YM, Ott DJ, Gelfand DW, Munitz HA. Multiphasic examination of the esophagogastric region for strictures, rings, and hiatal hernia: evaluation of the individual techniques. Gastrointest Radiol 1985; 10:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/61\">",
"      Somers S, Stevenson GW, Thompson G. Comparison of endoscopy and barium swallow with marshmallow in dysphagia. Can Assoc Radiol J 1986; 37:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/62\">",
"      Gallo SH, McClave SA, Makk LJ, Looney SW. Standardization of clinical criteria required for use of the 12.5 millimeter barium tablet in evaluating esophageal lumenal patency. Gastrointest Endosc 1996; 44:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/63\">",
"      Katz PO, Dalton CB, Richter JE, et al. Esophageal testing of patients with noncardiac chest pain or dysphagia. Results of three years' experience with 1161 patients. Ann Intern Med 1987; 106:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/64\">",
"      DiMarino AJ Jr, Allen ML, Lynn RB, Zamani S. Clinical value of esophageal motility testing. Dig Dis 1998; 16:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/65\">",
"      Dodds WJ. 1976 Walter B. Cannon Lecture: current concepts of esophageal motor function: clinical implications for radiology. AJR Am J Roentgenol 1977; 128:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/66\">",
"      Dent J, Holloway RH. Esophageal motility and reflux testing. State-of-the-art and clinical role in the twenty-first century. Gastroenterol Clin North Am 1996; 25:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/67\">",
"      Ginsberg GG. Management of ingested foreign objects and food bolus impactions. Gastrointest Endosc 1995; 41:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/68\">",
"      Longstreth GF, Longstreth KJ, Yao JF. Esophageal food impaction: epidemiology and therapy. A retrospective, observational study. Gastrointest Endosc 2001; 53:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/69\">",
"      Webb WA. Management of foreign bodies of the upper gastrointestinal tract: update. Gastrointest Endosc 1995; 41:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12569/abstract/70\">",
"      Vicari JJ, Johanson JF, Frakes JT. Outcomes of acute esophageal food impaction: success of the push technique. Gastrointest Endosc 2001; 53:178.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2241 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_17_12569=[""].join("\n");
var outline_f12_17_12569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEDICAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Peptic stricture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Esophageal webs and rings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Rings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Webs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cardiovascular abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radiation injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Achalasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Spastic motility disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H609924103\">",
"      Lymphocytic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Functional dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SPECIFIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Acute dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2241\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2241|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/33/32287\" title=\"algorithm 1\">",
"      Diagnosis of dysphagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?16/8/16527\" title=\"algorithm 2\">",
"      Diagnosis esophageal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2241|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/35/2623\" title=\"diagnostic image 1\">",
"      Esophageal web Ba swallow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/36/42574\" title=\"diagnostic image 2\">",
"      Schatzki ring Ba swallow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/35/37438\" title=\"diagnostic image 3\">",
"      Plummer Vinson syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/35/20016\" title=\"diagnostic image 4\">",
"      Classic achalasia Ba swallow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/55/24446\" title=\"diagnostic image 5\">",
"      Achalasia barium swallow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/9/39070\" title=\"diagnostic image 6\">",
"      Enlarged esophagus Chagas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/30/27118\" title=\"diagnostic image 7\">",
"      Diffuse esophageal spasm barium swallow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2241|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/40/30351\" title=\"picture 1\">",
"      Schatzki ring Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/18/28961\" title=\"picture 2\">",
"      Esophageal adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2241|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/49/1820\" title=\"table 1\">",
"      Dsyphagia questions patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/20/13644\" title=\"table 2\">",
"      Causes of esophageal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/35/2621\" title=\"table 3\">",
"      GI symptoms in scleroderma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=related_link\">",
"      Clinical manifestations and diagnosis of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19253?source=related_link\">",
"      Complications of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=related_link\">",
"      Diagnosis and treatment of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13096?source=related_link\">",
"      Diffuse esophageal spasm, nutcracker esophagus, and hypertensive lower esophageal sphincter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12838?source=related_link\">",
"      Esophageal webs and rings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=related_link\">",
"      Gastrointestinal manifestations of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=related_link\">",
"      Gastrointestinal toxicity of radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/19/21814?source=related_link\">",
"      Globus sensation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16568?source=related_link\">",
"      Motility testing: When does it help?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2037?source=related_link\">",
"      Pathogenesis and clinical manifestations of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19975?source=related_link\">",
"      Pathology and pathogenesis of Chagas disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43124?source=related_link\">",
"      Pathophysiology and etiology of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/13/7378?source=related_link\">",
"      Patient information: Dysphagia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/19/10546?source=related_link\">",
"      Patient information: Esophageal stricture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=related_link\">",
"      Vascular rings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_17_12570="Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction";
var content_f12_17_12570=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/17/12570/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/17/12570/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/17/12570/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/17/12570/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/17/12570/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/17/12570/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/17/12570/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/17/12570/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life-threatening ventricular arrhythmias &mdash; ventricular tachycardia (VT) and ventricular fibrillation (VF) &mdash; are infrequent but serious complications of an acute ST-elevation myocardial infarction (MI). The largest experience on the incidence of VT and VF during an acute ST elevation MI comes from the GUSTO-1 trial of 40,895 patients who were treated with thrombolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/1\">",
"     1",
"    </a>",
"    ]. The overall incidence of sustained VT or VF was 10.2 percent: 3.5 percent developed VT, 4.1 percent VF, and 2.7 percent both VT and VF. Approximately 80 to 85 percent of these arrhythmias occurred in the first 48 hours.",
"   </p>",
"   <p>",
"    Sustained ventricular arrhythmias are less common in patients with an acute non-ST elevation MI or unstable angina, as illustrated in a pooled analysis of four major trials of over 25,000 such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/2\">",
"     2",
"    </a>",
"    ]. The overall incidence of VT or VF was 2.1 percent, lower than the 10.2 percent incidence in GUSTO-1 in STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/3\">",
"     3",
"    </a>",
"    ]. VT occurred in 0.8 percent, VF in 1 percent, and VT and VF in 0.3 percent. The median time to arrhythmia was 78 hours.",
"   </p>",
"   <p>",
"    Sustained VT and VF in the setting of myocardial infarction result from the complex interaction of multiple factors, including myocardial ischemia, necrosis, reperfusion, healing, and scar formation. These events produce the mechanisms that initiate arrhythmias and the substrate for arrhythmia perpetuation. Arrhythmia pathogenesis varies at different stages in this process. For ventricular arrhythmias occurring more than 48 to 72 hours after an acute myocardial infarction (MI), scar formation is of primary importance.",
"   </p>",
"   <p>",
"    Ventricular arrhythmias during acute MI are typically classified based upon their time of onset. This scheme is useful clinically because VT and VF occurring early (&le;24 to 48 hours) have been thought to be epiphenomena of the MI and do not require long-term therapy because they are not associated with a worse prognosis after hospital discharge. In contrast, VT or VF occurring later is generally thought to reflect the development of arrhythmic substrate, and require chronic therapy because of an increased risk of sudden cardiac death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the mechanisms of arrhythmogenesis during acute MI, with particular attention to serious ventricular arrhythmias occurring in the first 48 to 72 hours. The clinical features and management of these arrhythmias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ARRHYTHMIA FORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular arrhythmias in the setting of acute MI result from an interplay among three basic components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The damaged myocardium, which produces a substrate capable of developing reentrant circuits. Complex ventricular arrhythmias are associated with larger infarctions and with early left ventricular dilatation and remodeling, perhaps due to ventricular stretching and electromechanical feedback [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Arrhythmia triggers, including spontaneous ventricular arrhythmias, variations in cycle length, and heart rate.",
"     </li>",
"     <li>",
"      Modulating factors, such as electrolyte imbalance (eg, hypokalemia), dysfunction of the autonomic nervous system (eg, increased sympathetic activity), continued ischemia, impaired left ventricular function, and elevated plasma levels of free fatty acids [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/6\">",
"       6",
"      </a>",
"      ]. These factors may act on both substrate and triggers to induce arrhythmias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The proper milieu for the development and maintenance of ventricular arrhythmias is ultimately based upon the rapid and profound effects that acute myocardial ischemia has on the electrophysiologic characteristics of the myocyte. Changes in the resting membrane potential and in the inward and outward ionic fluxes during the action potential lead to alterations in conduction, refractoriness, and automaticity of cardiac muscle cells, all of which contribute to the occurrence of ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increase in QT dispersion on the electrocardiogram, which reflects differences in ventricular repolarization times between normal myocardium and myocardium within the periinfarction ischemic zone, may predict an increase in risk for VF early in the course of a myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/8\">",
"     8",
"    </a>",
"    ]. Early coronary reperfusion after an acute myocardial infarction reduces QT dispersion which may diminish electrical instability [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26425?source=see_link\">",
"     \"QT dispersion: Measurement and interpretation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10778?source=see_link\">",
"     \"QT dispersion: Clinical applications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=see_link\">",
"     \"Coronary artery patency and outcome after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Changes in the resting membrane potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental coronary artery occlusion and resulting ischemia causes the resting membrane potential to become less negative via the following mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Loss of the energy dependent sodium-potassium-ATPase pump",
"     </li>",
"     <li>",
"      A decrease in potassium influx",
"     </li>",
"     <li>",
"      An increase in potassium efflux",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The net increase in potassium leakage out of the cells leads to a rise in the local extracellular potassium concentration from 4 to 15",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    within 15 minutes of coronary occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/12\">",
"     12",
"    </a>",
"    ]. Potassium accumulation occurs in two phases, since blood flow is absent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/11,13,14\">",
"     11,13,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first phase is reversible with reperfusion, provided it occurs within 15 minutes of occlusion.",
"     </li>",
"     <li>",
"      The second phase is irreversible and represents permanent cellular damage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Animal experiments have shown that the Na-K-ATPase pump is only mildly depressed in the early stages of ischemia (approximately 10 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/7\">",
"     7",
"    </a>",
"    ]. It has therefore been suggested that initial potassium loss is secondary to increased permeability of the cell membrane to anions, such as inorganic phosphate and lactate, or to the development of an intracellular acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/12,15\">",
"     12,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other products accumulating in the ischemic myocardium are lysophosphoglycerides (LPGs), which may mediate the following adverse electrophysiologic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolated normal myocardium and Purkinje fibers exposed to LPGs show electrical changes that are similar to those seen in ischemic myocardium [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/16-18\">",
"       16-18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Small amounts of LPGs augment the effect of hypoxia and elevated potassium, effects that are intensified by acidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High concentrations of LPGs cause disruption of the cell membrane, contributing to massive calcium entry and cell death [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The metabolic changes and acidosis that accompany occlusion and ischemia can be altered by multiple brief occlusions, as may occur in the patient with unstable angina or an acute myocardial infarction with ongoing episodes of ischemia. Studies using repetitive occlusions lasting less than five minutes have demonstrated a reduced incidence of VF; this phenomenon has been termed \"ischemic preconditioning\" [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=see_link\">",
"     \"Clinical implications of ischemic preconditioning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, longer periods of occlusion may not produce the same results. One animal study, for example, evaluated the effect of repetitive 15 minute coronary occlusions followed by 45 minute reperfusions on the incidence of occlusion and release arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/23\">",
"     23",
"    </a>",
"    ]. Repetitive occlusions were associated with progressively higher ST segment elevation, more frequent ST segment alternans, and a greater incidence of VF, suggesting increasing metabolic derangement. However, there was also faster normalization of the ECG and a reduced incidence of ventricular fibrillation during repetitive reperfusions, suggesting a progressively faster resolution of the metabolic derangements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Changes in the action potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute ischemia significantly reduces the amplitude, upstroke velocity, and duration of the action potential. The changes vary based upon the area of involvement.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The central ischemic zone has the largest alteration, consisting of a decrease in impulse velocity and an increase in the refractory period.",
"     </li>",
"     <li>",
"      The areas of normal myocardium surrounding the main area of infarction have an increase in impulse conduction velocity (due to catecholamines) and a shortened refractory period.",
"     </li>",
"     <li>",
"      The ischemic tissue at the border zone of the infarct manifests electrophysiologic changes that are intermediate between those found in the other two regions. This inhomogeneity is partly caused by diffusion of potassium that has leaked out of the cells in the ischemic areas toward more normal myocardium. In animals, ischemia at the border zone of a one-month old infarction is more arrhythmogenic that ischemia at a distance from the infarction zone [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Changes in the characteristics of the action potential upstroke cause a reduction in conduction velocity by approximately 50 percent during the first 5 to 10 minutes of ischemia. If ischemia continues, coupling resistance increases rapidly, indicating irreversible injury with a further reduction in impulse conduction between cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Acute phase (first 30 minutes) arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;A distinction must be made between the acute phase of myocardial ischemia (during the first 30 minutes) and the subacute or delayed phase (6 to 48 to 72 hours post-MI) when considering the mechanisms responsible for periinfarction ventricular arrhythmias. Acute and delayed arrhythmias are distinguished by clinical arrhythmia type, cellular mechanisms, and immediate prognostic implications.",
"   </p>",
"   <p>",
"    Arrhythmias occurring within the first 30 minutes of experimental coronary artery occlusion demonstrate the following bimodal distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arrhythmias occurring after the first 2 to 10 minutes are known as \"immediate\" or phase 1a ventricular arrhythmias and have a peak incidence after five minutes of ischemia.",
"     </li>",
"     <li>",
"      \"Delayed\" or phase 1b arrhythmias occur after approximately 10 to 60 minutes of coronary artery occlusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Experimental studies suggest that phase 1a and 1b arrhythmias arise via different mechanisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Phase 1a arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phase 1a arrhythmias occur when there is marked conduction slowing and delayed activation in the subepicardium, coincident with the decrease in resting membrane potential, partial membrane depolarization, and consequent reduction in membrane action potential amplitude [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/26\">",
"     26",
"    </a>",
"    ]. This results in marked slowing of impulse conduction and is detected as fractionation of local electrograms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/27\">",
"     27",
"    </a>",
"    ]. One phenomenon associated with the fractionated electrogram is diastolic bridging, which often precedes sustained ventricular arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the basis of these electrocardiographic findings, it has been postulated that",
"    <strong>",
"     reentry",
"    </strong>",
"    is the dominant mechanism behind phase 1a arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/27,29-31\">",
"     27,29-31",
"    </a>",
"    ]. It has also been suggested that during phase 1a, a nonreentry mechanism initiates isolated premature ventricular beats (VPBs), which in turn may precipitate reentrant arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible origin for this series of events is a focal mechanism such as triggered activity secondary to afterdepolarizations and abnormal automaticity. The latter changes result from spontaneous impulse formation based upon phase 4 depolarization in cells with reduced resting membrane potential [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/32\">",
"     32",
"    </a>",
"    ]. The occurrence of a focal mechanism is supported by a canine study using three dimensional activation mapping, which found that 60 percent of ventricular tachycardias in the early ischemic period were of focal Purkinje origin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42070?source=see_link\">",
"     \"Enhanced cardiac automaticity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Phase 1b arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism that gives rise to phase 1b arrhythmias has not been fully elucidated, but they may reflect abnormal automaticity, induced by left ventricular wall stress [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/34\">",
"     34",
"    </a>",
"    ] or the increased catecholamine release that occurs after 15 to 20 minutes of ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations suggests that sustained VT within the first few hours after MI may be the result of transient arrhythmogenic mechanisms, possibly resulting from ischemia, and its predictive value for sudden death is low. Consistent with this hypothesis is a report in which sustained monomorphic VT could not be induced in seven patients who had sustained monomorphic VT within 24 hours of the acute insult [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Delayed phase (6 to 72 hours) arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed phase arrhythmias generally occur between three to six hours and as long as two to three days after the onset of the MI. The most frequently observed ventricular arrhythmias are [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      VPBs",
"     </li>",
"     <li>",
"      Nonsustained VT (three to four beats)",
"     </li>",
"     <li>",
"      Accelerated idioventricular rhythm, which occurs in up to 50 percent of patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sustained ventricular arrhythmias are less common, but they can occur. It is generally believed that delayed arrhythmias arise from",
"    <strong>",
"     surviving Purkinje cells",
"    </strong>",
"    located within the subendocardium that display abnormal automaticity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/7,41\">",
"     7,41",
"    </a>",
"    ]. These cells have an increased sensitivity to catecholamines, and delayed arrhythmias can be provoked by stimulation of the sympathetic nervous system.",
"   </p>",
"   <p>",
"    An animal model suggested an alternative mechanism for arrhythmia occurring soon after acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/42\">",
"     42",
"    </a>",
"    ]. Four days after MI, prior to the development of fibrosis, there was marked disruption of gap-junctional distribution due to early remodeling of the myocardium. This resulted in nonuniformity of anisotropic conduction, which may lead to reentrant VT if the disruption extends through the full thickness of the myocardium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chronic phase arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the chronic, healing phase of an acute MI (more than 72 hours), the typical patient with sustained monomorphic VT has had a large, often complicated infarct with a left ventricular ejection fraction (LVEF) &le;30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The VT is often quite rapid in this setting, with a roughly equal distribution of heart rates above 220",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    between 180 to 220",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    and below 180",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    New ischemia can be superimposed upon this substrate with the appearance of a variety of ventricular arrhythmias including nonsustained, sustained monomorphic, polymorphic VT, and ventricular fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/45\">",
"     45",
"    </a>",
"    ]. Thus, revascularization and antiischemic therapy may be part of the antiarrhythmic regimen. Autonomic imbalance, electrolyte abnormalities, and the proarrhythmic effects of antiarrhythmic drugs can also contribute to the appearance of sustained monomorphic VT or other ventricular arrhythmias.",
"   </p>",
"   <p>",
"    Transient events, such as ischemia, autonomic surges, or VPBs may be difficult to document but may be important in selected patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 53 patients with spontaneous VT (44 with remote MI), the heart rate rose and measures of heart rate variability indicated a rise in sympathetic activity before the onset of the arrhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/46\">",
"       46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/10/4264?source=see_link\">",
"       \"Heart rate variability: Technical aspects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      One report evaluated the role of VPBs in 52 patients, 40 with CHD, who had an implantable cardioverter-defibrillator (ICD) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/47\">",
"       47",
"      </a>",
"      ]. Two-thirds of VT episodes were provoked by VPBs, which were most often multiple and had a morphology that was different from the VT. In another study using detailed electroanatomic mapping, 29 patients with ischemic cardiomyopathy and repeated episodes of VF were evaluated [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/48\">",
"       48",
"      </a>",
"      ]. In all subjects, VF was initiated by monomorphic VPBs originating in the border zone of the infarct scar. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link\">",
"       \"Clinical significance and treatment of ventricular premature beats\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inducibility and reentry &ndash; Sustained monomorphic VT can be initiated during electrophysiology study in approximately 90 to 95 percent of these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/43,49,50\">",
"       43,49,50",
"      </a>",
"      ]. The arrhythmia usually remains inducible after coronary artery bypass graft surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/50\">",
"       50",
"      </a>",
"      ]. Patients who have noninducible sustained monomorphic VT have a decreased probability of spontaneous VT, suggesting that the substrates for inducible and spontaneous VT may evolve in parallel over time [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings support the hypothesis that late sustained monomorphic VT is typically reentrant in origin. Experimental evidence in both the subacute and chronic phases after MI suggest that scar with the interdigitation of viable myocardium may provide the substrate for reentry [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Late potentials and slow conduction can occur in areas with normal action potentials; thus, slow conduction may be due to disruption of the gap junctional connections between cells by the collagen of the scar, resulting in nonuniformity of anisotropic conduction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reentry may occur around the area of infarction with a single circuit or two circuits. In a canine model of VT in healing MI, observed reentry circuits included [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Figure of eight",
"     </li>",
"     <li>",
"      Functional with long lines of functional block",
"     </li>",
"     <li>",
"      Short lines of functional block with slow conduction transverse to fiber orientation (anisotropic reentry)",
"     </li>",
"     <li>",
"      Leading circle reentry (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"       \"Reentry and the development of cardiac arrhythmias\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6774568\">",
"    <span class=\"h2\">",
"     Remodeling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular remodeling after an MI produces structural changes in the myocardium that may also be a factor in the pathogenesis of ventricular arrhythmia. In an analysis from the Survival and Ventricular Enlargement (SAVE) trial, transthoracic echocardiograms and 24-hour ambulatory ECG monitoring were performed at baseline and at one and two years in 263 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/56\">",
"     56",
"    </a>",
"    ]. Left ventricular size, muscle mass, and function were significantly correlated with the incidence of VT and with frequent VPBs. A similar correlation was found between ventricular arrhythmia and changes in left ventricular size and function over the two years of the study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19865?source=see_link\">",
"     \"Cardiac remodeling: Basic aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Role of the autonomic nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;A relative excess of sympathetic compared to vagal activity may be an important factor in genesis of ventricular arrhythmias during acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Autonomic imbalance can increase Na-K-ATPase pump activity and enhance potassium conductance of the myocardial cell membrane, both of which lead to hyperpolarization of the membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/59\">",
"     59",
"    </a>",
"    ]. Importantly, the effect of sympathetic stimulation (or excessive catecholamines) will vary depending upon the state of the myocardium; this will enhance underlying myocardial electrical heterogeneity, which is an important precondition for ventricular arrhythmia.",
"   </p>",
"   <p>",
"    Support for the role of the sympathetic nervous system comes from a study of 49 patients who had electrical storm, defined as multiple recurrent episodes of VF, associated with an acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/60\">",
"     60",
"    </a>",
"    ]. Compared to patients receiving antiarrhythmic therapy, those treated with sympathetic blockade (beta blockers or stellate ganglionic blockade) had a lower one week mortality (22 versus 82 percent) and overall mortality at one year (33 versus 95 percent).",
"   </p>",
"   <p>",
"    The longer term important of the role of sympathetic activity comes from the clear evidence of reduced mortality, including arrhythmic death, in patients treated with beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indirect clinical evidence supporting a role for reduced parasympathetic tone are the observations that decreased baroreflex sensitivity and impaired heart rate variability (which reflect reduced vagal activity) are associated with increased inducibility of sustained monomorphic VT and with sudden death during the first 6 to 12 months after a myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. However, extrapolation of these findings to the acute phase of MI is at present not justified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Abnormalities in cardiac innervation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial infarction may be associated with inhomogeneous distribution of sympathetic fibers. Regions with necrosis and dense scarring show myocardial denervation. In contrast, other regions of the myocardium may show an increase in sympathetic innervation, possibly the result of injury-related nerve sprouting. Immunocytochemical staining of tissue from patients with severe heart failure, due to either an idiopathic cardiomyopathy or a myocardial infarction, found that patients with a history of spontaneous ventricular arrhythmias had regional hyperinnervation, with an increase in sympathetic nerve fibers in the perivascular regions and the periphery of injured myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sympathetic efferent fibers en route to the left ventricle cross at the atrioventricular groove, travel within the superficial subepicardium in a base-to-apex direction, and penetrate the myocardium to innervate the endocardium. A transmural MI can damage the sympathetic fibers and result in functional denervation of the myocardium apical to the area of the infarction. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Animal and human studies have shown that, after infarction, regions of the ventricular myocardium below the infarcted zone have no uptake of iodine-123-metaiodobenzylguanidine (MIBG), a radiolabeled guanethidine analog that is actively taken up by sympathetic nerve terminals, even though this tissue remains viable, as indicated by persistent thallium uptake [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/66-68\">",
"       66-68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Denervated regions show denervation hypersensitivity to infused norepinephrine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      , as manifested by a greater shortening in refractoriness compared to normal myocardial tissue or easier inducibility of sustained VT during sympathetic stimulation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/69,70\">",
"       69,70",
"      </a>",
"      ]. The resulting heterogeneity in refractoriness induced by circulating catecholamines is a potential mechanism for arrhythmogenicity after infarction that can be minimized by beta blockers [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/69\">",
"       69",
"      </a>",
"      ]. In comparison, regional denervation may not affect the inducibility of sustained VT at electrophysiology study [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reinnervation of the periinfarction area, but not the infarcted tissue, and the loss of supersensitivity occur within 12 months after the infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Role of thrombus and ischemic preconditioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of life-threatening ventricular arrhythmias in the presence of intracoronary thrombus is greater than that associated with coronary artery ligation or balloon occlusion, despite a similar amount of ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. In an animal study, for example, an increased incidence of VF due to more conduction slowing during the first few minutes was noted with ischemia induced by intracoronary thrombus compared to coronary artery ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/73\">",
"     73",
"    </a>",
"    ]. The electrophysiologic effect of the thrombus lasted only a few minutes, suggesting an association between thrombin and the rapid release of ischemic metabolites, such as LPGs and lysophosphatidylcholines, and their accumulation in ventricular myocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/16,17,74\">",
"     16,17,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The profibrillatory effect of the thrombus in the above report was not detectable after ischemic preconditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/73\">",
"     73",
"    </a>",
"    ]. This may account, in part, for the observation that a sudden obstruction of the coronary artery without preexisting coronary artery narrowing is associated with a higher incidence of ventricular fibrillation compared to an obstruction occurring in association with preexisting stenoses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=see_link\">",
"     \"Clinical implications of ischemic preconditioning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Reperfusion arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular arrhythmias in some patients have been thought to be related to reperfusion, occurring within a period of minutes after reperfusion has been achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. The evidence is best for an accelerated idioventricular rhythm (AIVR) as a reperfusion arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/76-80\">",
"     76-80",
"    </a>",
"    ], although AIVR is neither a sensitive nor very specific marker for successful reperfusion. The most common reperfusion changes involve the ST segment and T waves (eg, ST segment elevation resolution) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serious ventricular arrhythmia induced by reperfusion does not appear to a major problem [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. As an example, large trials of intravenous thrombolytic therapy did not demonstrate any increase in life-threatening arrhythmias that could be attributed to reperfusion, although frequent VPBs and accelerated idioventricular rhythms did occur and might have been a marker of reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Similar findings have been noted after primary percutaneous coronary intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/80\">",
"     80",
"    </a>",
"    ]. Although sustained VT and VF may be associated temporally with reperfusion, they are often associated with persistent occlusion not patency of the infarct-related artery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/78,84\">",
"     78,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reperfusion arrhythmias may be one manifestation of reperfusion injury, which also includes vascular damage (no reflow phenomenon), myocardial stunning, accelerated necrosis of reversibly damaged cells, and cell swelling and accelerated necrosis of irreversibly damaged myocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/85\">",
"     85",
"    </a>",
"    ]. In addition, with reperfusion there is a washout of substances that have accumulated after the ischemic injury, including potassium. The electrolyte imbalance may result in reperfusion arrhythmia. Reperfusion injury is thought to be mediated by three main mechanisms, although angiotensin II also may contribute. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6394?source=see_link\">",
"     \"Ischemic reperfusion injury of the heart\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The calcium paradox &ndash; The calcium paradox occurs when calcium is restored to the extracellular space after having been depleted by ischemia. This ensuing accumulation of calcium in the cell causes damage to the respiratory chain and decreases ATP production, leading to depletion of mitochondrial energy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/86\">",
"       86",
"      </a>",
"      ]. Severe cell damage ensues with muscle contracture and cell death.",
"     </li>",
"     <li>",
"      The oxygen paradox &ndash; The oxygen paradox is closely linked to the calcium paradox since oxygen mediates the uptake of calcium by the mitochondria [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/87\">",
"       87",
"      </a>",
"      ]. Recycling of calcium occurs when ATP is restored during reperfusion, with the subsequent possibility of developing calcium-dependent arrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/88,89\">",
"       88,89",
"      </a>",
"      ]. Oxygen also leads to cell damage during reperfusion by the formation of oxygen free radicals [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The production of oxygen free radicals &ndash; The role of oxygen free radicals in the genesis of reperfusion arrhythmias is uncertain. Free radical-induced membrane damage occurs 5 to 10 minutes after reperfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/91\">",
"       91",
"      </a>",
"      ], and reduced levels of free radical scavengers have been observed within three hours of angioplasty in patients with an infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/92\">",
"       92",
"      </a>",
"      ]. Reperfusion arrhythmias, however, usually occur within seconds after abrupt restoration of blood flow. The observation that free radicals reduce the occurrence of reperfusion ventricular fibrillation is also against their playing a primary role in reperfusion arrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Angiotensin II &ndash; A role for angiotensin II in reperfusion arrhythmias was suggested by studies in angiotensin II type 1a receptor knockout mice which, compared to wild-type mice, showed less reperfusion arrhythmia despite a similar infarct size. Furthermore, administration with a selective angiotensin II type 1 receptor before ischemia blocked reperfusion arrhythmias in the wild-type mice [",
"      <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/94\">",
"       94",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=see_link\">",
"       \"Actions of angiotensin II on the heart\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of reperfusion arrhythmias is influenced by the severity and duration of ischemia. The concept that reperfusion arrhythmias are energy-dependent and arise from salvaged myocardium is supported by the observation that arrhythmias do not arise from dead cells.",
"   </p>",
"   <p>",
"    The occurrence of reperfusion arrhythmias follows a bell-shaped curve: as the duration of ischemia increases in experimental animals, so do reperfusion arrhythmias. The peak incidence occurs at 5 to 10 minutes after the onset of ischemia, presumably due to depletion of ATP stores [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/87,89\">",
"     87,89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical experience is different from these largely experimental observations of reperfusion arrhythmias. Thrombolytic therapy is typically given more than two to four hours after the onset of coronary occlusion, when significant infarction is already present; the same is true of primary percutaneous coronary intervention. It therefore seems likely that",
"    <strong>",
"     ischemia rather than reperfusion",
"    </strong>",
"    is responsible for the majority of serious ventricular arrhythmias seen in patients with acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?12/17/12570/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arrhythmias that may be due to reperfusion should be managed in an identical fashion to other arrhythmias in the acute MI setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/51/27442?source=see_link\">",
"       \"Patient information: Ventricular tachycardia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H246729\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Life-threatening ventricular arrhythmias&mdash;ventricular tachycardia (VT) and ventricular fibrillation (VF)&mdash;are infrequent but serious complications of an acute myocardial infarction (MI), with the vast majority occurring within 48 hours of the onset of symptoms. VT and VF in the setting of myocardial infarction result from the complex interaction of multiple factors, including myocardial ischemia, necrosis, reperfusion, healing, and scar formation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventricular arrhythmias in the setting of acute MI result from an interplay among three basic components: injured myocardium, which produces a substrate capable of developing reentrant circuits; arrhythmia triggers (eg, variations in cycle length); and modulating factors (eg, electrolyte imbalance, ongoing ischemia). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms of arrhythmia formation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute myocardial ischemia results in several changes to the resting membrane potential as well as the action potential. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Changes in the resting membrane potential'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Changes in the action potential'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute phase arrhythmias, occurring within 30 minutes of the onset of myocardial ischemia, are divided into two subgroups:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Phase 1a arrhythmias, occurring within 10 minutes of the onset of myocardial ischemia, are felt to result from reentry. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Phase 1a arrhythmia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Phase 1b arrhythmias, occurring 10 to 30 minutes after the onset of myocardial ischemia, have an undetermined mechanism but may be due to abnormal automaticity. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Phase 1b arrhythmia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delayed phase arrhythmias generally occur between three to six hours and as long as two to three days after the onset of the MI and are generally believed to arise from surviving Purkinje cells located within the subendocardium that display abnormal automaticity. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Delayed phase (6 to 72 hours) arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic phase arrhythmias occurring more than 72 hours after the onset of myocardial ischemia are related to the formation of myocardial scar tissue and the development of reentrant circuits. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chronic phase arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A relative excess of sympathetic compared to vagal activity may be an important factor in the genesis of ventricular arrhythmias during acute MI. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Role of the autonomic nervous system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventricular arrhythmias in some patients have been thought to be related to reperfusion, occurring within a period of minutes after reperfusion has been achieved. Arrhythmias that may be due to reperfusion should be managed in an identical fashion to other arrhythmias in the acute MI setting. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Reperfusion arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/1\">",
"      Newby KH, Thompson T, Stebbins A, et al. Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. Circulation 1998; 98:2567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/2\">",
"      Al-Khatib SM, Granger CB, Huang Y, et al. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes. Circulation 2002; 106:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/3\">",
"      Sobel BE, Corr PB, Robison AK, et al. Accumulation of lysophosphoglycerides with arrhythmogenic properties in ischemic myocardium. J Clin Invest 1978; 62:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/4\">",
"      Hansen DE, Craig CS, Hondeghem LM. Stretch-induced arrhythmias in the isolated canine ventricle. Evidence for the importance of mechanoelectrical feedback. Circulation 1990; 81:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/5\">",
"      Popovi AD, Neskovi AN, Pavlovski K, et al. Association of ventricular arrhythmias with left ventricular remodelling after myocardial infarction. Heart 1997; 77:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/6\">",
"      Tansey MJ, Opie LH. Relation between plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction. Lancet 1983; 2:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/7\">",
"      Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989; 69:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/8\">",
"      Yunus A, Gillis AM, Duff HJ, et al. Increased precordial QTc dispersion predicts ventricular fibrillation during acute myocardial infarction. Am J Cardiol 1996; 78:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/9\">",
"      Endoh Y, Kasanuki H, Ohnishi S, et al. Influence of early coronary reperfusion on QT interval dispersion after acute myocardial infarction. Pacing Clin Electrophysiol 1997; 20:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/10\">",
"      Downar E, Janse MJ, Durrer D. The effect of acute coronary artery occlusion on subepicardial transmembrane potentials in the intact porcine heart. Circulation 1977; 56:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/11\">",
"      Guarnieri T, Strauss HC. Intracellular potassium activity in guinea pig papillary muscle during prolonged hypoxia. J Clin Invest 1982; 69:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/12\">",
"      Kl&eacute;ber AG. Resting membrane potential, extracellular potassium activity, and intracellular sodium activity during acute global ischemia in isolated perfused guinea pig hearts. Circ Res 1983; 52:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/13\">",
"      Hill JL, Gettes LS. Effect of acute coronary artery occlusion on local myocardial extracellular K+ activity in swine. Circulation 1980; 61:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/14\">",
"      Hirche H, Franz C, B&ouml;s L, et al. Myocardial extracellular K+ and H+ increase and noradrenaline release as possible cause of early arrhythmias following acute coronary artery occlusion in pigs. J Mol Cell Cardiol 1980; 12:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/15\">",
"      Rau EE, Shine KI, Langer GA. Potassium exchange and mechanical performance in anoxic mammalian myocardium. Am J Physiol 1977; 232:H85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/16\">",
"      Arnsdorf MF, Sawicki GJ. The effects of lysophosphatidylcholine, a toxic metabolite of ischemia, on the components of cardiac excitability in sheep Purkinje fibers. Circ Res 1981; 49:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/17\">",
"      Clarkson CW, Ten Eick RE. On the mechanism of lysophosphatidylcholine-induced depolarization of cat ventricular myocardium. Circ Res 1983; 52:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/18\">",
"      Corr PB, Cain ME, Witkowski FX, et al. Potential arrhythmogenic electrophysiological derangements in canine Purkinje fibers induced by lysophosphoglycerides. Circ Res 1979; 44:822.",
"     </a>",
"    </li>",
"    <li>",
"     Basset AL, Gelband H, Nilsson K, et al. Electrophysiology following healed experimental myocardial infarction. In: Reentrant Arrhythmias: Mechanisms and Treatment, Kulbertus HE (Ed), MTP Press, Lancaster, England 1979. p.242.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/20\">",
"      Corr PB, Yamada KA, Creer MH, et al. Lysophosphoglycerides and ventricular fibrillation early after onset of ischemia. J Mol Cell Cardiol 1987; 19 Suppl 5:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/21\">",
"      Katz AM. Membrane-derived lipids and the pathogenesis of ischemic myocardial damage. J Mol Cell Cardiol 1982; 14:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/22\">",
"      Vegh A, Komori S, Szekeres L, Parratt JR. Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats. Cardiovasc Res 1992; 26:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/23\">",
"      Figueras J, Segura R, Bermejo B. Repeated 15-minute coronary occlusions in pigs increase occlusion arrhythmias but decrease reperfusion arrhythmias that are associated with extracellular hypokalemia. J Am Coll Cardiol 1996; 28:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/24\">",
"      Cinca J, Blanch P, Carre&ntilde;o A, et al. Acute ischemic ventricular arrhythmias in pigs with healed myocardial infarction: comparative effects of ischemia at a distance and ischemia at the infarct zone. Circulation 1997; 96:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/25\">",
"      HARRIS AS. Delayed development of ventricular ectopic rhythms following experimental coronary occlusion. Circulation 1950; 1:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/26\">",
"      Bigger JT Jr, Dresdale FJ, Heissenbuttel RH, et al. Ventricular arrhythmias in ischemic heart disease: mechanism, prevalence, significance, and management. Prog Cardiovasc Dis 1977; 19:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/27\">",
"      Boineau J, Cox JL. Slow ventricular. A source of re-entrant premature contraction. Circulation 1973; 48:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/28\">",
"      El-Sherif N, Scherlag BJ, Lazzara R, Hope RR. Re-entrant ventricular arrhythmias in the late myocardial infarction period. 1. Conduction characteristics in the infarction zone. Circulation 1977; 55:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/29\">",
"      Kaplinsky E, Ogawa S, Balke CW, Dreifus LS. Two periods of early ventricular arrhythmia in the canine acute myocardial infarction model. Circulation 1979; 60:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/30\">",
"      Scherlag BJ, Helfant RH, Haft JI, Damato AN. Electrophysiology underlying ventricular arrhythmias due to coronary ligation. Am J Physiol 1970; 219:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/31\">",
"      Waldo AL, Kaiser GA. A study of ventricular arrhythmias associated with acute myocardial infarction in the canine heart. Circulation 1973; 47:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/32\">",
"      Hoffman BF, Rosen MR. Cellular mechanisms for cardiac arrhythmias. Circ Res 1981; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/33\">",
"      Arnar DO, Bullinga JR, Martins JB. Role of the Purkinje system in spontaneous ventricular tachycardia during acute ischemia in a canine model. Circulation 1997; 96:2421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/34\">",
"      Coronel R, Wilms-Schopman FJ, deGroot JR. Origin of ischemia-induced phase 1b ventricular arrhythmias in pig hearts. J Am Coll Cardiol 2002; 39:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/35\">",
"      Carlsson L, Abrahamsson T, Almgren O, Svensson L. Ischaemia-induced release of noradrenaline and creatine kinase in the isolated, working rat heart. Acta Physiol Scand 1987; 130:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/36\">",
"      Sch&ouml;mig A, Dart AM, Dietz R, et al. Release of endogenous catecholamines in the ischemic myocardium of the rat. Part A: Locally mediated release. Circ Res 1984; 55:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/37\">",
"      Penny WJ. The deleterious effects of myocardial catecholamines on cellular electrophysiology and arrhythmias during ischaemia and reperfusion. Eur Heart J 1984; 5:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/38\">",
"      Wellens HJ, D&uuml;ren DR, Lie KI. Observations on mechanisms of ventricular tachycardia in man. Circulation 1976; 54:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/39\">",
"      Campbell RW, Murray A, Julian DG. Ventricular arrhythmias in first 12 hours of acute myocardial infarction. Natural history study. Br Heart J 1981; 46:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/40\">",
"      Northover BJ. Ventricular tachycardia during the first 72 hours after acute myocardial infarction. Cardiology 1982; 69:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/41\">",
"      Sugi K, Karagueuzian HS, Fishbein MC, et al. Spontaneous ventricular tachycardia associated with isolated right ventricular infarction, one day after right coronary artery occlusion in the dog: studies on the site of origin and mechanism. Am Heart J 1985; 109:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/42\">",
"      Peters NS, Coromilas J, Severs NJ, Wit AL. Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation 1997; 95:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/43\">",
"      Marchlinski FE, Buxton AE, Waxman HL, Josephson ME. Identifying patients at risk of sudden death after myocardial infarction: value of the response to programmed stimulation, degree of ventricular ectopic activity and severity of left ventricular dysfunction. Am J Cardiol 1983; 52:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/44\">",
"      DiMarco JP, Lerman BB, Kron IL, Sellers TD. Sustained ventricular tachyarrhythmias within 2 months of acute myocardial infarction: results of medical and surgical therapy in patients resuscitated from the initial episode. J Am Coll Cardiol 1985; 6:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/45\">",
"      Stambler BS, Akosah KO, Mohanty PK, et al. Myocardial ischemia and induction of sustained ventricular tachyarrhythmias: evaluation using dobutamine stress echocardiography-electrophysiologic testing. J Cardiovasc Electrophysiol 2004; 15:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/46\">",
"      Shusterman V, Aysin B, Gottipaty V, et al. Autonomic nervous system activity and the spontaneous initiation of ventricular tachycardia. ESVEM Investigators. Electrophysiologic Study Versus Electrocardiographic Monitoring Trial. J Am Coll Cardiol 1998; 32:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/47\">",
"      Saeed M, Link MS, Mahapatra S, et al. Analysis of intracardiac electrograms showing monomorphic ventricular tachycardia in patients with implantable cardioverter-defibrillators. Am J Cardiol 2000; 85:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/48\">",
"      Marrouche NF, Verma A, Wazni O, et al. Mode of initiation and ablation of ventricular fibrillation storms in patients with ischemic cardiomyopathy. J Am Coll Cardiol 2004; 43:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/49\">",
"      Marchlinski FE, Waxman HL, Buxton AE, Josephson ME. Sustained ventricular tachyarrhythmias during the early postinfarction period: electrophysiologic findings and prognosis for survival. J Am Coll Cardiol 1983; 2:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/50\">",
"      Brugada J, Aguinaga L, Mont L, et al. Coronary artery revascularization in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction: effects on the electrophysiologic substrate and outcome. J Am Coll Cardiol 2001; 37:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/51\">",
"      Gillis AM, Sheldon RS, Wyse DG, et al. Long-term reproducibility of ventricular tachycardia induction in patients with implantable cardioverter/defibrillators. Serial noninvasive studies. Circulation 1995; 91:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/52\">",
"      El-Sherif N, Smith RA, Evans K. Canine ventricular arrhythmias in the late myocardial infarction period. 8. Epicardial mapping of reentrant circuits. Circ Res 1981; 49:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/53\">",
"      Wit AL, Allessie MA, Bonke FI, et al. Electrophysiologic mapping to determine the mechanism of experimental ventricular tachycardia initiated by premature impulses. Experimental approach and initial results demonstrating reentrant excitation. Am J Cardiol 1982; 49:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/54\">",
"      Ursell PC, Gardner PI, Albala A, et al. Structural and electrophysiological changes in the epicardial border zone of canine myocardial infarcts during infarct healing. Circ Res 1985; 56:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/55\">",
"      Kanaan N, Robinson N, Roth SI, et al. Ventricular tachycardia in healing canine myocardial infarction: evidence for multiple reentrant mechanisms. Pacing Clin Electrophysiol 1997; 20:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/56\">",
"      St John Sutton M, Lee D, Rouleau JL, et al. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation 2003; 107:2577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/57\">",
"      Schwartz PJ, Stone HL, Brown AM. Effects of unilateral stellate ganglion blockade on the arrhythmias associated with coronary occlusion. Am Heart J 1976; 92:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/58\">",
"      Schwartz PJ, Vanoli E, Stramba-Badiale M, et al. Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. Circulation 1988; 78:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/59\">",
"      Boyden PA, Cranefield PF, Gadsby DC. Noradrenaline hyperpolarizes cells of the canine coronary sinus by increasing their permeability to potassium ions. J Physiol 1983; 339:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/60\">",
"      Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm : sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation 2000; 102:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/61\">",
"      Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/62\">",
"      La Rovere MT, Specchia G, Mortara A, Schwartz PJ. Baroreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction. A prospective study. Circulation 1988; 78:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/63\">",
"      Farrell TG, Paul V, Cripps TR, et al. Baroreflex sensitivity and electrophysiological correlates in patients after acute myocardial infarction. Circulation 1991; 83:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/64\">",
"      Cripps TR, Malik M, Farrell TG, Camm AJ. Prognostic value of reduced heart rate variability after myocardial infarction: clinical evaluation of a new analysis method. Br Heart J 1991; 65:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/65\">",
"      Cao JM, Fishbein MC, Han JB, et al. Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation 2000; 101:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/66\">",
"      Iwasaki T, Suzuki T, Tateno M, et al. Dual-tracer autoradiography with thallium-201 and iodine-125-metaiodobenzylguanidine in experimental myocardial infarction of rat. J Nucl Med 1996; 37:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/67\">",
"      Nishimura T, Oka H, Sago M, et al. Serial assessment of denervated but viable myocardium following acute myocardial infarction in dogs using iodine-123 metaiodobenzylguanidine and thallium-201 chloride myocardial single photon emission tomography. Eur J Nucl Med 1992; 19:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/68\">",
"      Stanton MS, Tuli MM, Radtke NL, et al. Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine. J Am Coll Cardiol 1989; 14:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/69\">",
"      Inoue H, Zipes DP. Results of sympathetic denervation in the canine heart: supersensitivity that may be arrhythmogenic. Circulation 1987; 75:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/70\">",
"      Herre JM, Wetstein L, Lin YL, et al. Effect of transmural versus nontransmural myocardial infarction on inducibility of ventricular arrhythmias during sympathetic stimulation in dogs. J Am Coll Cardiol 1988; 11:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/71\">",
"      Hartikainen J, Kuikka J, M&auml;ntysaari M, et al. Sympathetic reinnervation after acute myocardial infarction. Am J Cardiol 1996; 77:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/72\">",
"      Goldstein JA, Butterfield MC, Ohnishi Y, et al. Arrhythmogenic influence of intracoronary thrombosis during acute myocardial ischemia. Circulation 1994; 90:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/73\">",
"      Coronel R, Wilms-Schopman FJ, Janse MJ. Profibrillatory effects of intracoronary thrombus in acute regional ischemia of the in situ porcine heart. Circulation 1997; 96:3985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/74\">",
"      McHowat J, Corr PB. Thrombin-induced release of lysophosphatidylcholine from endothelial cells. J Biol Chem 1993; 268:15605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/75\">",
"      Gressin V, Louvard Y, Pezzano M, Lardoux H. Holter recording of ventricular arrhythmias during intravenous thrombolysis for acute myocardial infarction. Am J Cardiol 1992; 69:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/76\">",
"      Gorgels AP, Vos MA, Letsch IS, et al. Usefulness of the accelerated idioventricular rhythm as a marker for myocardial necrosis and reperfusion during thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1988; 61:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/77\">",
"      Goldberg S, Greenspon AJ, Urban PL, et al. Reperfusion arrhythmia: a marker of restoration of antegrade flow during intracoronary thrombolysis for acute myocardial infarction. Am Heart J 1983; 105:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/78\">",
"      Miller FC, Krucoff MW, Satler LF, et al. Ventricular arrhythmias during reperfusion. Am Heart J 1986; 112:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/79\">",
"      Yoshida Y, Hirai M, Yamada T, et al. Antiarrhythmic efficacy of dipyridamole in treatment of reperfusion arrhythmias : evidence for cAMP-mediated triggered activity as a mechanism responsible for reperfusion arrhythmias. Circulation 2000; 101:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/80\">",
"      Wehrens XH, Doevendans PA, Ophuis TJ, Wellens HJ. A comparison of electrocardiographic changes during reperfusion of acute myocardial infarction by thrombolysis or percutaneous transluminal coronary angioplasty. Am Heart J 2000; 139:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/81\">",
"      Hackett D, McKenna W, Davies G, Maseri A. Reperfusion arrhythmias are rare during acute myocardial infarction and thrombolysis in man. Int J Cardiol 1990; 29:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/82\">",
"      Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/83\">",
"      Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986; 1:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/84\">",
"      Berger PB, Ruocco NA, Ryan TJ, et al. Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. J Am Coll Cardiol 1993; 22:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/85\">",
"      Matsumura K, Jeremy RW, Schaper J, Becker LC. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 1998; 97:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/86\">",
"      Opie LH. Reperfusion injury and its pharmacologic modification. Circulation 1989; 80:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/87\">",
"      Opie LH, Coetzee WA. Role of calcium ions in reperfusion arrhythmias: relevance to pharmacologic intervention. Cardiovasc Drugs Ther 1988; 2:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/88\">",
"      Lee JA, Allen DG. Changes in intracellular free calcium concentration during long exposures to simulated ischemia in isolated mammalian ventricular muscle. Circ Res 1992; 71:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/89\">",
"      Coetzee WA, Opie LH. Effects of components of ischemia and metabolic inhibition on delayed afterdepolarizations in guinea pig papillary muscle. Circ Res 1987; 61:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/90\">",
"      Hearse DJ, Tosaki A. Free radicals and calcium: simultaneous interacting triggers as determinants of vulnerability to reperfusion-induced arrhythmias in the rat heart. J Mol Cell Cardiol 1988; 20:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/91\">",
"      Ambrosio G, Weisfeldt ML, Jacobus WE, Flaherty JT. Evidence for a reversible oxygen radical-mediated component of reperfusion injury: reduction by recombinant human superoxide dismutase administered at the time of reflow. Circulation 1987; 75:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/92\">",
"      Lafont A, Marwick TH, Chisolm GM, et al. Decreased free radical scavengers with reperfusion after coronary angioplasty in patients with acute myocardial infarction. Am Heart J 1996; 131:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/93\">",
"      Saman S, Coetzee WA, Opie LH. Inhibition by simulated ischemia or hypoxia of delayed afterdepolarizations provoked by cyclic AMP: significance for ischemic and reperfusion arrhythmias. J Mol Cell Cardiol 1988; 20:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/17/12570/abstract/94\">",
"      Harada K, Komuro I, Hayashi D, et al. Angiotensin II type 1a receptor is involved in the occurrence of reperfusion arrhythmias. Circulation 1998; 97:315.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 65 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_17_12570=[""].join("\n");
var outline_f12_17_12570=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H246729\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF ARRHYTHMIA FORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Changes in the resting membrane potential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Changes in the action potential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Acute phase (first 30 minutes) arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Phase 1a arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Phase 1b arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Delayed phase (6 to 72 hours) arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chronic phase arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6774568\">",
"      Remodeling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Role of the autonomic nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Abnormalities in cardiac innervation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Role of thrombus and ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Reperfusion arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H246729\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19865?source=related_link\">",
"      Cardiac remodeling: Basic aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=related_link\">",
"      Clinical implications of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=related_link\">",
"      Clinical significance and treatment of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=related_link\">",
"      Coronary artery patency and outcome after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42070?source=related_link\">",
"      Enhanced cardiac automaticity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/10/4264?source=related_link\">",
"      Heart rate variability: Technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6394?source=related_link\">",
"      Ischemic reperfusion injury of the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/51/27442?source=related_link\">",
"      Patient information: Ventricular tachycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10778?source=related_link\">",
"      QT dispersion: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26425?source=related_link\">",
"      QT dispersion: Measurement and interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_17_12571="Epilepsy syndromes in first year of life";
var content_f12_17_12571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Epilepsy syndromes with onset in the first year of life",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Benign neonatal convulsions (familial and non-familial)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign familial infantile convulsions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paroxysmal kinesigenic dyskinesia/infantile convulsions*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early infantile epileptic encephalopathy (Ohtahara's Syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early myoclonic encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infantile massive spasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign partial epilepsy with and without secondary generalization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign myoclonic epilepsy in infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe myoclonic epilepsy in infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lennox-Gastaut syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Childhood absence epilepsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptomatic/cryptogenic partial epilepsies",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Also known as familial infantile convulsions and paroxysmal choreoathetosis (ICCA).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_17_12571=[""].join("\n");
var outline_f12_17_12571=null;
var title_f12_17_12572="Median survival advanced ca";
var content_f12_17_12572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Median survivals from studies that include untreated patients with advanced cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tumor histology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disease stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median survival*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colorectal adenocarcinoma",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        5 to 6 months",
"       </td>",
"       <td>",
"        Scheithauer 1993",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric adenocarcinoma",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        5 months",
"       </td>",
"       <td>",
"        Glimelius 1997",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head and neck squamous cell carcinoma",
"       </td>",
"       <td>",
"        IV/recurrent",
"       </td>",
"       <td>",
"        4 months",
"       </td>",
"       <td>",
"        Kowalski 2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Non-small cell lung cancer",
"       </td>",
"       <td rowspan=\"3\">",
"        IIIb/IV",
"       </td>",
"       <td>",
"        4.1 months",
"       </td>",
"       <td>",
"        Roszkowski 2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5.3 months",
"       </td>",
"       <td>",
"        Attali 1987",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5.9 months",
"       </td>",
"       <td>",
"        Cellerino 1991",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Advanced disease\"",
"       </td>",
"       <td>",
"        2.5 months",
"       </td>",
"       <td>",
"        Meta-analysis, BMJ 1995",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatocellular carcinoma",
"       </td>",
"       <td>",
"        Unresectable",
"       </td>",
"       <td>",
"        4.2 to 8 months",
"       </td>",
"       <td>",
"        Llovet 2008, Cheng 2009",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Pancreatic adenocarcinoma",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        7 months",
"       </td>",
"       <td>",
"        Huguier 2001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV, following failure of front-line gemcitabine chemotherapy (locally advanced inoperable or metastatic)",
"       </td>",
"       <td>",
"        2.3 months",
"       </td>",
"       <td>",
"        Pelzer 2011",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Values pertain to the subset of untreated patients.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_17_12572=[""].join("\n");
var outline_f12_17_12572=null;
var title_f12_17_12573="Preventive services";
var content_f12_17_12573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medicare preventive services",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Screening test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Eligible",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Initial Preventive Physical Examination (IPPE)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Once, during first 12 months of enrollment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Cardiovascular screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum cholesterol or lipid panel",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Every five years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abdominal aortic aneurysm (AAA)",
"       </td>",
"       <td>",
"        Men with smoking history; family history AAA",
"       </td>",
"       <td>",
"        Once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Breast cancer screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mammogram",
"       </td>",
"       <td>",
"        Women age &gt;40 years (one baseline age 35 to 39 years)",
"       </td>",
"       <td>",
"        Annual",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Cervical cancer screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pap smear and pelvic exam",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Annual if high risk, or childbearing age with abnormal Pap test within past three years; biannual for all other women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Colon cancer screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        FOBT",
"       </td>",
"       <td>",
"        Age &gt;50 years",
"       </td>",
"       <td>",
"        Annual",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexible sigmoidoscopy",
"       </td>",
"       <td>",
"        Age &gt;50 years",
"       </td>",
"       <td>",
"        Every four years or once every 10 years after having a screening colonoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Colonoscopy",
"       </td>",
"       <td>",
"        Age &gt;50 years",
"       </td>",
"       <td>",
"        Every 24 months at high risk; every 10 years not at high risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Barium enema",
"       </td>",
"       <td>",
"        Age &gt;50 years",
"       </td>",
"       <td>",
"        Every 24 months at high risk; every 4 years not at high risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Prostate cancer screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PSA and DRE",
"       </td>",
"       <td>",
"        Men age &gt;50 years",
"       </td>",
"       <td>",
"        Annual",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Influenza vaccine",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Once per influenza season in the fall or winter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumococcal vaccine",
"       </td>",
"       <td>",
"        High risk or &gt;65 years (all medicare recipients)",
"       </td>",
"       <td>",
"        Once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B vaccine",
"       </td>",
"       <td>",
"        High risk",
"       </td>",
"       <td>",
"        Scheduled dosages required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone densitometry",
"       </td>",
"       <td>",
"        Women age &gt;50 years, or high risk",
"       </td>",
"       <td>",
"        Biannual",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Diabetes screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fasting plasma glucose",
"       </td>",
"       <td>",
"        High risk (hypertension, hyperlipidemia, obesity)",
"       </td>",
"       <td>",
"        Semiannual for beneficiaries diagnosed with pre-diabetes; annual if previously tested but not diagnosed with pre-diabetes, or if never tested",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glaucoma screening",
"       </td>",
"       <td>",
"        High risk (diabetes, family history, African American age &gt;50 years; Hispanic Americans age &gt;65 years)",
"       </td>",
"       <td>",
"        Annual",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smoking and tobacco use cessation counseling",
"       </td>",
"       <td>",
"        Tobacco users with adverse health effects",
"       </td>",
"       <td>",
"        Up to 8 sessions in a 12 month period",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AAA: abdominal aortic aneurysm; FOBT: fecal occult blood test; PSP: prostate specific antigen; DRE: digital rectal examination.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_17_12573=[""].join("\n");
var outline_f12_17_12573=null;
var title_f12_17_12574="Contents: Epilepsy and EEG";
var content_f12_17_12574=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/63/1022\">",
"       Neurology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Epilepsy and EEG",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Epilepsy and EEG",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/42/32425\">",
"           Electroencephalography (EEG) in the diagnosis of seizures and epilepsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/52/2890\">",
"           Evaluation and management of drug-resistant epilepsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/9/25753\">",
"           Evaluation of the first seizure in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/21/22871\">",
"           Magnetic resonance imaging changes related to acute seizure activity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/49/13082\">",
"           Neuroimaging in the evaluation of seizures and epilepsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/41/18074\">",
"           Nonepileptic paroxysmal disorders in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/28/33226\">",
"           Psychogenic nonepileptic seizures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/0/15368\">",
"           Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathophysiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/32/37385\">",
"           Pathophysiology of seizures and epilepsy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Psychosocial issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/51/32568\">",
"           Driving restrictions for patients with seizures and epilepsy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Special populations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/59/23480\">",
"           Catamenial epilepsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/1/23578\">",
"           Localization-related (partial) epilepsy: Causes and clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/16/15625\">",
"           Management of epilepsy and pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/52/4935\">",
"           Post-traumatic seizures and epilepsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/6/22633\">",
"           Risks associated with epilepsy and pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/56/40841\">",
"           Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/6/17512\">",
"           Treatment of seizures and epilepsy in the elderly patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/4/31818\">",
"           Initial treatment of epilepsy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/39/40570\">",
"           Overview of the management of epilepsy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/61/43994\">",
"           Pharmacology of antiepileptic drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/16/18697\">",
"           Seizures in patients with primary and metastatic brain tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/11/19642\">",
"           Status epilepticus in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/6/1128\">",
"           Sudden unexpected death in epilepsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/39/41593\">",
"           Surgical therapy of epilepsy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/7/19578\">",
"           Vagus nerve stimulation therapy for the treatment of epilepsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/38/28264\">",
"           Valproic acid poisoning",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-8C30615775-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f12_17_12574=[""].join("\n");
var outline_f12_17_12574=null;
var title_f12_17_12575="MRCP stone post Roux-en-Y";
var content_f12_17_12575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRCP showing large distally impacted bile duct stone in patient post Roux-en-Y gastric bypass with jaundice",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 249px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of ML Freeman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_17_12575=[""].join("\n");
var outline_f12_17_12575=null;
